[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 97 of about 97
1. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood; 2008 Mar 15;111(6):3183-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
  • To determine whether miRNAs are associated with cytogenetic abnormalities and clinical features in acute myeloid leukemia (AML), we evaluated the miRNA expression of CD34(+) cells and 122 untreated adult AML cases using a microarray platform.
  • An independent set of 60 untreated AML patients was used to validate the outcome signatures using real-time polymerase chain reaction.
  • We identified several miRNAs differentially expressed between CD34(+) normal cells and the AML samples. miRNA expression was also closely associated with selected cytogenetic and molecular abnormalities, such as t(11q23), isolated trisomy 8, and FLT3-ITD mutations.
  • Furthermore, patients with high expression of miR-191 and miR-199a had significantly worse overall and event-free survival than AML patients with low expression (overall survival: miR-191, P = .03; and miR-199a, P = .001, Cox regression).
  • In conclusion, miRNA expression in AML is closely associated with cytogenetics and FLT3-ITD mutations.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2004 Oct;18(10):1565-8 [15452588.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6133-40 [17404574.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1550-7 [15973452.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Cell. 2005 Dec 2;123(5):819-31 [16325577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):357-64 [12139719.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cancer Biol Ther. 2003 Mar-Apr;2(2):164-70 [12750556.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Science. 2004 Apr 23;304(5670):594-6 [15105502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 [15210942.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5078-83 [16549775.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5 [17293455.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1130-4 [17554337.001]
  • [Cites] Blood. 1997 Jan 15;89(2):630-43 [9002967.001]
  • (PMID = 18187662.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / P01CA76259; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P01 CA076259; United States / NCI NIH HHS / CA / P01CA81534; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / P01 CA055164
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2265455
  •  go-up   go-down


2. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS: Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med; 2009 Sep 24;361(13):1249-59
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracycline dose intensification in acute myeloid leukemia.
  • BACKGROUND: In young adults with acute myeloid leukemia (AML), intensification of the anthracycline dose during induction therapy has improved the rate of complete remission but not of overall survival.
  • METHODS: In this phase 3 randomized trial, we assigned 657 patients between the ages of 17 and 60 years who had untreated AML to receive three once-daily doses of daunorubicin at either the standard dose (45 mg per square meter of body-surface area) or a high dose (90 mg per square meter), combined with seven daily doses of cytarabine (100 mg per square meter) by continuous intravenous infusion.
  • CONCLUSIONS: In young adults with AML, intensifying induction therapy with a high daily dose of daunorubicin improved the rate of complete remission and the duration of overall survival, as compared with the standard dose. (ClinicalTrials.gov number, NCT00049517. )

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Massachusetts Medical Society
  • [CommentIn] N Engl J Med. 2009 Dec 24;361(26):2578; author reply 2578 [20032330.001]
  • [CommentIn] N Engl J Med. 2009 Sep 24;361(13):1301-3 [19776412.001]
  • (PMID = 19776406.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00049517
  • [Grant] United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / U10 CA013650; United States / NCI NIH HHS / CA / U10 CA014958; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / CA13650; United States / NCI NIH HHS / CA / U10 CA017145; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / U10 CA073590; United States / NCI NIH HHS / CA / U10 CA014548; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / U10 CA015488
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / MLL protein, human; 04079A1RDZ / Cytarabine; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS435676; NLM/ PMC4480917
  •  go-up   go-down


3. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M: Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood; 2009 Apr 30;113(18):4179-87
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.
  • Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit for intensive treatment because of the risk of fatal toxicity.
  • The Swedish Acute Leukemia Registry covers 98% of all patients with AML (nonacute promyelocytic leukemia) diagnosed in 1997 to 2005 (n = 2767), with a median follow-up of 5 years, and reports eligibility for intensive therapy, performance status (PS), complete remission rates, and survival.
  • Total survival of elderly AML patients was better in the geographic regions where most of them were given standard intensive therapy.
  • This analysis provides unique real world data from a large, complete, and unselected AML population, both treated and untreated, and gives background to treatment decisions for the elderly.
  • Most AML patients up to 80 years of age should be considered fit for intensive therapy, and new therapies must be compared with standard induction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Decision Making. Female. Humans. Male. Middle Aged. Prognosis. Registries. Survival Rate. Sweden. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2009 Apr 30;113(18):4129-30 [19406994.001]
  • (PMID = 19008455.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud Ø: Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol; 2010;11:38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.
  • BACKGROUND: Several observations suggest that immunological events early after chemotherapy, possibly during the period of severe treatment-induced cytopenia, are important for antileukemic immune reactivity in acute myeloid leukemia (AML).
  • We therefore investigated the frequencies of various T cell subsets (TC1, TH1, TH17) and CD25+ FoxP3+ TREG cells in AML patients with untreated disease and following intensive chemotherapy.
  • Increased levels of regulatory CD25+ FoxP3+ T cells were detected in AML patients with untreated disease, during chemotherapy-induced cytopenia and during regeneration after treatment.
  • Finally, exogenous IL17-A usually had no or only minor effects on proliferation of primary human AML cells.
  • CONCLUSIONS: We conclude that the effect of intensive AML chemotherapy differ between circulating T cell subsets, relative frequencies of TH17 cells are not affected by chemotherapy and this subset may affect AML cells indirectly through their immunoregulatory effects but probably not through direct effects of IL17-A.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Movement / immunology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / immunology. T-Lymphocyte Subsets / drug effects. T-Lymphocytes, Helper-Inducer / drug effects. T-Lymphocytes, Regulatory / drug effects
  • [MeSH-minor] Adult. Antigens, CD3 / metabolism. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / pathology. Female. Forkhead Transcription Factors / metabolism. Health. Humans. Interleukin-2 Receptor alpha Subunit / metabolism. Leukopenia / chemically induced. Leukopenia / immunology. Male. Middle Aged. Sex Characteristics. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] Clin Exp Immunol. 2009 Nov;158(2):199-204 [19737137.001]
  • [Cites] Cell Immunol. 2000 Nov 25;206(1):36-50 [11161436.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1137-40 [11466326.001]
  • [Cites] Microbes Infect. 2001 Sep;3(11):911-8 [11564439.001]
  • [Cites] J Cell Biochem Suppl. 2002;38:88-95 [12046855.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1311-8 [12094255.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] J Hematother Stem Cell Res. 2003 Oct;12(5):525-35 [14594509.001]
  • [Cites] Haematologica. 2004 Apr;89(4):391-402 [15075072.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jun;50(3):197-222 [15182826.001]
  • [Cites] Cell. 2004 Jul 23;118(2):217-28 [15260991.001]
  • [Cites] Leukemia. 1987 Jan;1(1):52-7 [2444829.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Feb;7(1):47-64 [8449864.001]
  • [Cites] Scand J Immunol. 1998 Jan;47(1):54-62 [9467659.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3206-13 [15618466.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(9):835-57 [15778723.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1362-8 [15845901.001]
  • [Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]
  • [Cites] Leukemia. 2006 Jan;20(1):29-34 [16281063.001]
  • [Cites] Nature. 2006 May 11;441(7090):231-4 [16648837.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):1037-42 [16708062.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1119-28 [16699530.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):919-27 [16920557.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jan;56(1):13-24 [16612597.001]
  • [Cites] Nat Med. 2007 Feb;13(2):139-45 [17290272.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jun;56(6):913-25 [17115221.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]
  • [Cites] Hematology. 2007 Jun;12(3):199-207 [17558695.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3192-201 [17616639.001]
  • [Cites] Immunol Rev. 2007 Dec;220:22-34 [17979837.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2495-505 [17898786.001]
  • [Cites] Semin Immunol. 2007 Oct;19(5):318-30 [18023361.001]
  • [Cites] Gut. 2008 Jun;57(6):772-9 [17965063.001]
  • [Cites] Immunol Res. 2008;41(2):87-102 [18172584.001]
  • [Cites] J Clin Immunol. 2008 Nov;28(6):660-70 [18810613.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Dec;8(8):666-75 [19075589.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3325-32 [19417016.001]
  • [Cites] Genes Immun. 2009 Jul;10(5):509-16 [19279650.001]
  • [Cites] J Interferon Cytokine Res. 2000 Nov;20(11):947-54 [11096451.001]
  • (PMID = 20618967.001).
  • [ISSN] 1471-2172
  • [Journal-full-title] BMC immunology
  • [ISO-abbreviation] BMC Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antineoplastic Agents; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-2 Receptor alpha Subunit
  • [Other-IDs] NLM/ PMC2912832
  •  go-up   go-down


5. Hamurcu Z, Dönmez-Altuntas H, Patiroglu T: Basal level micronucleus frequency in stimulated lymphocytes of untreated patients with leukemia. Cancer Genet Cytogenet; 2008 Jan 15;180(2):140-4
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal level micronucleus frequency in stimulated lymphocytes of untreated patients with leukemia.
  • Structural chromosomal aberrations have been described in various types of human leukemia.
  • The present study investigated micronucleus (MN) frequency in mitogen-stimulated peripheral blood lymphocytes from 20 newly diagnosed and untreated leukemia patients: 4 with acute lymphoblastic leukemia (ALL), 10 with acute myeloid leukemia (AML), and 6 with chronic lymphocytic leukemia (CLL).
  • The mean MN frequency for untreated patients was 3.65 +/- 1.47 in ALL, 3.55 +/- 1.24 in AML, 3.03 +/- 1.05 in CLL.
  • No differences in MN frequency were seen between leukemia types ALL, AML, and CLL (P = 0.503).
  • The mean basal MN frequency for all patients, regardless of leukemia type, was 3.41 +/- 1.19, which was significantly higher (P = 0.001) than that of 20 age-matched control subjects, 1.87 +/- 0.75.
  • Although no significant relationship was found between age and MN frequency in patients with leukemia (r = 0.050; P = 0.835), the MN frequency in the lymphocytes of healthy control increased regularly and significantly with age (r = 0.531; P = 0.016).
  • These data indicate that the increased baseline MN frequency in lymphocytes of untreated patients with leukemia may reflect genomic instability or deficiency of DNA repair capacity.
  • [MeSH-major] Leukemia / genetics. Lymphocytes / metabolism. Micronuclei, Chromosome-Defective / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Female. Humans. Male. Micronucleus Tests. Middle Aged

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206540.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Ruan GR, Chen SS, Ma X, Chang Y, Wan H, Fu JY, Qin YZ, Li JL, Liu YR: [Abnormal expression of PDCD5 in the bone marrow cells of adult acute myeloid leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun;15(3):462-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abnormal expression of PDCD5 in the bone marrow cells of adult acute myeloid leukemia].
  • The objective of this study was to estimate a novel apoptosis-promoting molecule PDCD5 expression in the bone marrow cells from adult acute myeloid leukemia (AML) for investigation of its significance in the pathogenesis of AML.
  • Flow cytometry assay was used for detection of PDCD5 expression in the different groups of cells from bone marrow of AML patients and normal controls by using 21 monoclonal antibodies with different fluorescent markers.
  • The PDCD5 expressions in bone marrow cells from some AML patients and normal controls were also detected by Western blot.
  • The results showed that the mean PDCD5 fluorescence intensity in bone marrow nucleated cells (MNC) from the bone marrow of 36 untreated AML patients was significantly lower than that from the bone marrow of 30 normal controls (3059 +/- 1392) vs (7432 +/- 1261) (P < 0.01).
  • The mean PDCD5 fluorescence intensity was lower in the marrow granulocytes, monocytes, blast cells, and lymphocytes from untreated AML patients than that from normal (3939 +/- 2121) vs (8367 +/- 1045); (3156 +/- 1635) vs (5917 +/- 2329); (2824 +/- 1592) vs (3998 +/- 2106); (1474 +/- 816) vs (3355 +/- 2042) respectively, (all P < 0.01).
  • Western blot analysis demonstrated that PDCD5 expression was significantly decreased in the AML cells, as compared with normal cells.
  • It is concluded that PDCD5 expression in MNC in untreated AML patients is lower than that in the normal.
  • PDCD5 expression in the marrow granulocytes, monocytes, blast cells, and lymphocytes of untreated AML patients is significantly lower than that in the normal.
  • It suggests that the abnormally low expression of PDCD5 may be involved in the pathogenesis of AML.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17605845.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins; 0 / PDCD5 protein, human
  •  go-up   go-down


7. Wu WL, Liang JY, Zhu MQ, Xue YQ, Chen ZX: [MIC categorization of acute lymphoblastic leukemia with myeloid surface antigen expression]. Zhonghua Xue Ye Xue Za Zhi; 2007 Nov;28(11):754-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MIC categorization of acute lymphoblastic leukemia with myeloid surface antigen expression].
  • OBJECTIVE: To explore the characteristics of morphology, immunophenotype and cytogenetics (MIC) of myeloid surface antigen-expressing acute lymphoblastic leukemia (My+ ALL).
  • METHODS: One hundred and twenty untreated acute lymphoblastic leukemia (ALL) patients were diagnosed by standard bone marrow smear morphologic analysis and peroxidase staining.
  • Flow cytometry and myeloid monoclonal antibodies (McAb) were used to analyze immunophenotype.
  • Of 66 My+ ALL, 10 cases (15.1%) were misdiagnosed as acute non-lymphoblastic leukemia (ANLL), the other 54 My- ALL cases were correctly diagnosed.
  • Some cases have a myeloid morphologic appearance and might be misdiagnosed as acute myeloid leukemia (AML).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunophenotyping. Karyotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457267.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Chiaretti S, Messina M, Tavolaro S, Zardo G, Elia L, Vitale A, Fatica A, Gorello P, Piciocchi A, Scappucci G, Bozzoni I, Fozza C, Candoni A, Guarini A, Foà R: Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. Haematologica; 2010 Jul;95(7):1114-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223.
  • BACKGROUND: Until recently, few molecular aberrations were recognized in acute lymphoblastic leukemia of T-cell origin; novel lesions have recently been identified and a certain degree of overlap between acute myeloid leukemia and T-cell acute lymphoblastic leukemia has been suggested.
  • To identify novel T-cell acute lymphoblastic leukemia entities, gene expression profiling was performed and clinico-biological features were studied.
  • DESIGN AND METHODS: Sixty-nine untreated adults with T-cell acute lymphoblastic leukemia were evaluated by oligonucleotide arrays: unsupervised and supervised analyses were performed.
  • The up-regulation of myeloid genes and miR-223 expression were validated by quantitative polymerase chain reaction analysis.
  • Of these, one branch included seven patients whose gene expression profile resembled that of acute myeloid leukemia.
  • These cases were characterized by over-expression of a large set of myeloid-related genes for surface antigens, transcription factors and granule proteins.
  • We, therefore, evaluated the expression levels of miR-223, involved in myeloid differentiation: these cases had significantly higher levels of miR-223 than had the other cases of T-cell acute lymphoblastic leukemia, with values comparable to those observed in acute myeloid leukemia.
  • CONCLUSIONS: Using gene profiling we identified a subset of adult T-cell acute lymphoblastic leukemia, accounting for 10% of the cases analyzed, which displays myeloid features.
  • These cases were not recognized by standard approaches, underlining the importance of gene profiling in identifying novel acute leukemia subsets.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Leukemia, Myeloid, Acute / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adult. Humans


9. Laurent S, Palmisano GL, Martelli AM, Kato T, Tazzari PL, Pierri I, Clavio M, Dozin B, Balbi G, Megna M, Morabito A, Lamparelli T, Bacigalupo A, Gobbi M, Pistillo MP: CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. Br J Haematol; 2007 Feb;136(4):597-608
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis.
  • We have previously reported that about 80% of acute myeloid leukaemia (AML) samples tested at diagnosis constitutively expressed cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4).
  • The present study compared CTLA-4 expression and function of leukaemic cells from AML patients at diagnosis with those from AML patients resistant to conventional chemotherapy.
  • We also explored the possibility of targeting CTLA-4 for apoptosis induction in chemoresistant AML cells.
  • AML cells either from untreated patients (n = 15) or in chemoresistant phase (n = 10) were analysed for CTLA-4 protein and transcript expression by flow cytometry and reverse transcription-polymerase chain reaction respectively.
  • CTLA-4 expression was similar in untreated and in chemoresistant samples and was not associated with patients' clinical features.
  • In chemoresistant AML cells, CTLA-4 transduced an apoptotic signal on engagement with its recombinant ligands r-CD80 and r-CD86, which induced an average of 71% and 62% apoptotic cells, respectively, at highest concentration.
  • Apoptosis was equally induced in untreated leukaemic cells accompanied by cleavage of procaspase-8 and -3.
  • Thus, this study provides the first evidence that killing of leukaemic cells from AML patients may be obtained by the engagement of CTLA-4 with its ligands, opening the way to a novel potential therapeutic approach based on triggering the CTLA-4 molecule to circumvent chemoresistance in AML.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation / metabolism. Antigens, Neoplasm / metabolism. Apoptosis. Leukemia, Myeloid / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD80 / metabolism. Antigens, CD86 / metabolism. CTLA-4 Antigen. Caspases / metabolism. Drug Resistance, Neoplasm. Female. Humans. Ligands. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367412.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD80; 0 / Antigens, CD86; 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / CD86 protein, human; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Ligands; EC 3.4.22.- / Caspases
  •  go-up   go-down


10. Wrobel T, Mazur G, Kapelko K, Kuliczkowski K: Endostatin serum level in acute myeloid leukemia. Neoplasma; 2005;52(2):182-4
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endostatin serum level in acute myeloid leukemia.
  • Increased levels of tumor angiogenesis have been demonstrated in variety of solid tumors and hematological malignancies including acute myeloid leukemia (AML).
  • The aim of the study was to evaluate serum level of endostatin in newly diagnosed patients with AML before chemotherapy and after achieving complete remission (CR).
  • Serum samples from 68 adult patients (28 females and 40 males, median age 42 years, range 21-83 years) with AML had been taken before chemotherapy was administered.
  • Endostatin serum levels were significantly higher in untreated AML patients than in the normal controls.
  • In AML patients baseline endostatin levels were significantly lower than in CR.
  • Moreover endostatin levels did not differ statistically among AML FAB subgroups.
  • Increased endostatin plasma levels may reflect intensity of inhibition of angiogenesis and may by useful in prognosis of CR in AML.
  • Chemotherapy can modulate the regulation of angiogenesis in AML patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Endostatins / blood. Leukemia, Myeloid / pathology. Neovascularization, Pathologic
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Bone Marrow / pathology. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800718.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Endostatins
  •  go-up   go-down


11. Kreuter M, Woelke K, Bieker R, Schliemann C, Steins M, Buechner T, Berdel WE, Mesters RM: Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia; 2006 Nov;20(11):1950-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia.
  • The importance of NRP-1 in hematological malignancies such as acute myeloid leukemia (AML) remains to be elucidated.
  • Therefore, we determined NRP-1 expression by immunohistochemical analysis of bone marrow biopsies of patients with newly diagnosed, untreated AML.
  • The expression of NRP-1 was significantly increased in AML patients (n = 76; median 12.9 arbitrary units (a.u.
  • In conclusion, our data provide evidence of increased NRP-1 expression in AML with significant correlation to survival.
  • Thus, NRP-1 might constitute a promising target for antileukemic and antiangiogenic treatment strategies in AML.
  • [MeSH-major] Leukemia, Myeloid / metabolism. Leukemia, Myeloid / mortality. Neuropilin-1 / metabolism
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Biopsy. Bone Marrow / metabolism. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neovascularization, Physiologic / physiology. Survival Rate

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990775.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 144713-63-3 / Neuropilin-1
  •  go-up   go-down


12. Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglunds M, Karlsson K, Stockelberg D, Wahlin A, Aström M, Arnesson C, Brunell-Abrahamsson U, Carstensen J, Fredriksson E, Holmberg E, Nordenskjöld K, Wiklund F, Swedish Adult Acute Leukemia Registry Group: Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia; 2006 Jan;20(1):42-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
  • Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking.
  • The remission intention (RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown.
  • The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries.
  • Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region (range 36-76%) and the two-year overall survival, with no censored observations (6-21%) (chi-squared for trend=11.3, P<0.001; r2=0.86, P<0.02, nonparametric).
  • Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction.
  • [MeSH-major] Attitude of Health Personnel. Leukemia, Myeloid / drug therapy. Patient Selection
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Follow-Up Studies. Humans. Middle Aged. Registries. Remission Induction. Survival Rate. Sweden / epidemiology. Treatment Outcome


13. Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS: A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900. J Clin Oncol; 2009 May 20;27(15_suppl):7003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900.
  • : 7003 Background: In younger adults with newly diagnosed acute myeloid leukemia (AML), anthracycline dose intensification during induction may improve complete remission (CR) rates; however, an improvement in overall survival (OS) in a randomized trial has not been demonstrated.
  • METHODS: Adult patients with previously untreated AML were randomized to receive either SDD (45 mg/m<sup>2</sup>/d) or HDD (90 mg/m<sup>2</sup>/d) each for 3days combined with standard-dose cytarabine (100 mg/m<sup>2</sup>/d) for 7 days by continuous intravenous infusion.
  • In younger AML patients a higher dose of anthracycline in induction should be considered the new standard of care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961375.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Qin YZ, Li JL, Zhu HH, Li LD, Chang Y, Le H, Ruan GR, Liu YR, Huang XJ, Chen SS: [Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique]. Zhonghua Xue Ye Xue Za Zhi; 2007 Jul;28(7):433-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique].
  • OBJECTIVE: To evaluate levels of common specific fusion transcripts M-bcr-abl, m-bcr-abl, TEL-AML1, AML1-ETO, PML-RAR alpha, CBF beta-MYH11 in untreated leukemia patients.
  • METHODS: Specific fusion transcript levels were detected by TaqMan-based real-time quantitative RT-PCR technique in a total of 208 samples, including 195 bone marrow samples from 50 M-bcr-abl(+) chronic phase-chronic myeloid leukemia (CML-CP), 10 M-bcr-abl(+) acute lymphoblastic leukemia (ALL), 19 m-bcr-abl(+) ALL, 11 TEL-AML1(+) ALL, 30 AML1-ETO(+) acute myeloid leukemia (AML), 58 PML-RAR alpha(+) acute promyelocytic leukemia (APL) and 17 CBF beta-MYH11(+) AML patients and 13 peripheral blood samples from 13 M-bcr-abl(+) CML-CP patients. abl was chosen as internal control gene.
  • Among AML patients, AML1-ETO level was significantly higher than CBF beta-MYH11 and PML-RAR alpha levels (median 388% vs 145%, 388% vs 47%, all P < 0.001), CBF beta-MYH11 level was significantly higher than PML-RAR alpha level (P < 0.001).
  • CONCLUSIONS: Fusion transcript levels in untreated leukemia patients were different and patient-to-patient variations did exist.
  • Detection of fusion transcript levels in untreated leukemia patients not only provides baseline for minimal residual disease monitoring and treatment evaluation but also enable the comparison in inter-laboratory data.
  • [MeSH-major] Leukemia / genetics. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Cells / metabolism. Child. Child, Preschool. Core Binding Factor Alpha 2 Subunit / genetics. Female. Fusion Proteins, bcr-abl / genetics. Humans. Male. Middle Aged. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072623.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / CBFbeta-MYH11 fusion protein; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


15. van der Heiden PL, Jedema I, Willemze R, Barge RM: Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Eur J Haematol; 2006 May;76(5):409-13
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
  • Patients with acute myeloid leukemia (AML) at diagnosis and relapsed AML were treated with 6 and 9 mg/m(2) GO.
  • The overall response (OR) in patients with AML at diagnosis was 47%, with the best response in patients with primary AML (OR 60%, compared with 21% OR in non-primary AML, P = 0.045).
  • The OR in patients with relapsed AML was 22%.
  • This report shows that GO has potent clinical activity and that the OR rate was by far the best in untreated primary AML patients.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Antibodies, Monoclonal, Humanized. Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Disease Progression. Female. Humans. Kinetics. Leukocyte Count. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Sialic Acid Binding Ig-like Lectin 3. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480432.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  •  go-up   go-down


16. Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, Alonzo TA: Mortality in overweight and underweight children with acute myeloid leukemia. JAMA; 2005 Jan 12;293(2):203-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality in overweight and underweight children with acute myeloid leukemia.
  • CONTEXT: Current treatment for acute myeloid leukemia (AML) in children cures about half the patients.
  • Of the other half, most succumb to leukemia, but 5% to 15% die of treatment-related complications.
  • Overweight children with AML seem to experience excess life-threatening and fatal toxicity.
  • Nothing is known about how weight affects outcomes in pediatric AML.
  • OBJECTIVE: To compare survival rates in children with AML who at diagnosis are underweight (body mass index [BMI] < or =10th percentile), overweight (BMI > or =95th percentile), or middleweight (BMI = 11th-94th percentiles).
  • DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of BMI and survival in 768 children and young adults aged 1 to 20 years enrolled in Children's Cancer Group-2961, an international cooperative group phase 3 trial for previously untreated AML conducted August 30, 1996, through December 4, 2002.
  • CONCLUSION: Treatment-related complications significantly reduce survival in overweight and underweight children with AML.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644547.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098413; United States / NCI NIH HHS / CA / CA098543
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


17. Visani G, Olivieri A, Malagola M, Brunori M, Piccaluga PP, Capelli D, Pomponio G, Martinelli G, Isidori A, Sparaventi G, Leoni P: Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine. Leuk Lymphoma; 2006 Jun;47(6):1091-102
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine.
  • Post-remission therapy in acute myeloid leukemia (AML) remains problematic.
  • The purpose of our study was to identify the most important randomized and controlled studies comparing these three therapeutic options, in order to draw conclusions and possible suggestions for post-remission therapy of AML, according to the evidence based medicine (EBM) rules.
  • We searched the MEDLINE computer database for reports from 1985 through January 2005 and selected for analysis the clinical trials conducted over adults affected by newly diagnosed AML aged less than 65 years.
  • 1) is auto-SCT superior to ICC/no other therapy in improving DFS and/or OS in adult AML patients in first CR?
  • 2) is allo-SCT superior to auto-SCT/other therapeutic options in improving DFS and/or OS in adult AML patients in first CR?
  • Moreover, the scarce data concerning the comparison between auto-SCT and chemotherapy in different subsets of patients are unable to suggest a differentiated approach in patients with high-risk, standard-risk or low-risk AML.
  • Concerning the second query, interpretation of data from the main prospective studies about the role of allo-SCT in previously untreated AML is not easy.
  • The first problem is the lack of real randomized clinical trials; in fact, according to the reported studies, AML patients generally receive allo-SCT on the basis of donor availability (the so called "genetic randomization").
  • In conclusion, the EBM approach highlighted the limitations observed in the published studies concerning consolidation therapy in AML; some suggestions, emerging from non-randomized, as well as randomized studies, are adequate, but not conclusive.
  • This point, coupled with the intrinsic complexity to study AML biological heterogeneity, is probably a major obstacle to draw conclusive evidences for consolidation therapy in AML.
  • These observations should plan to address new randomized studies on AML therapy; however, due to the emergence of genetic subgroups and new drugs targeting specific abnormalities, these trials should probably be designed directly focusing on the single entities.
  • In this way, the cure of AML could eventually become the cure of each specific AML subset with its peculiar biological, molecular and prognostic features.
  • [MeSH-major] Evidence-Based Medicine. Leukemia, Myeloid, Acute / drug therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Agents / pharmacology. Clinical Trials as Topic / methods. Disease-Free Survival. Humans. Remission Induction. Research Design. Transplantation, Homologous. Treatment Outcome


18. Zhang Y, Zhang MR, Yang L, Xiao ZJ: [Study of nucleophosmin (NPM) gene mutation in patients with acute myeloid leukemia and myelodysplastic syndromes]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jul;27(7):470-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of nucleophosmin (NPM) gene mutation in patients with acute myeloid leukemia and myelodysplastic syndromes].
  • OBJECTIVE: To investigate nucleophosmin (NPM) gene mutations in patients with de novo acute myeloid leukemia (AML) with normal cytogenetics and primary myelodysplastic syndromes (MDS).
  • METHODS: Genomic DNA corresponding to exon 12 of NPM gene was amplified by polymerase chain reaction (PCR) in 40 AML patients (28 case untreated and 12 in first remission) and 33 MDS patients.
  • RESULTS: NPM mutations were found in 6 patients (4 newly diagnosed AML and 2 MDS): 4 were type A,1 type B, and 1 novel sequence variant ( named as type R).
  • The results provides new hints for NPM gene mutations in the pathogenesis of AML and MDS.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Karyotyping. Male. Middle Aged. Mutation


19. Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami MR, Donahue AC, Ravandi F, Estey E, O'Brien S, Keating M, Giles FJ, Albitar M: Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomark; 2009;5(1):51-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
  • Roughly one-third of acute myeloid leukemia (AML) patients exhibit mutations in the nucleophosmin (NPM1) gene, and multiple studies have linked these mutations with a more favorable clinical outcome.
  • Analyzing plasma from previously untreated AML patients revealed NPM1 insertion mutations in 24 of 98 (24%) patients, with greater sensitivity than existing peripheral blood cell-based tests which showed positivity in only 22 of the 24 patients.
  • These data underline the significance of NPM1 in the biology and clinical behavior of AML, and demonstrate the reliability and efficacy of plasma-based testing for NPM1 mutations.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Mutation / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Sequence. DNA Mutational Analysis. Humans. Middle Aged. Molecular Sequence Data. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242062.001).
  • [ISSN] 1574-0153
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


20. Xiao R, Chen T, Zhou M, Yang JH, Jiang NK, Zhang R: [Abnormal expression of hematopoietic regulatory factors in newly diagnosed patients with acute myeloid leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1124-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abnormal expression of hematopoietic regulatory factors in newly diagnosed patients with acute myeloid leukemia].
  • The aim of this study was to detect the expressions of transforming growth factor (TGFβ(1)), tumor necrosis factor alpha (TNFα) and leukemia inhibitory factor (LIF) in newly diagnosed patients with acute myeloid leukemia (AML) and investigate the association between serum levels of various cytokines and clinical outcomes.
  • The results showed that levels of TGFβ1, TNFα and LIF were elevated in AML patients as compared with the controls (13.08±9.77 ng/ml, 10.67±15.11 pg/ml, 4.23±4.73 pg/ml vs 8.23±3.12 ng/ml, 5.86±3.05 pg/ml, 2.78±1.22 pg/ml) (p all<0.05).
  • It is concluded that TGFβ1, TNFα and LIF expressions showed increased level in the untreated patients with de novo AML, the TGFβ1 level among which is associated with the prognosis of patients.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129244.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leukemia Inhibitory Factor; 0 / Transforming Growth Factor beta1; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


21. Lee DH, Chung NG, Cho B, Kim HK, Kang HJ, Shin HY, Ahn HS, Yoo KH, Sung KW, Koo HH, Kook H, Hwang TJ, Im HJ, Seo JJ, Park HJ: Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea. J Korean Med Sci; 2010 Jan;25(1):9-15
Hazardous Substances Data Bank. THIOGUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
  • We investigated the outcome of idarubicin plus N(4)-behenoyl-1-beta-D-arabinofuranosyl cytosine (BHAC)-based chemotherapy (BHAC group, n=149) compared to idarubicin plus cytarabine-based chemotherapy (cytarabine group, n=191) for childhood acute myeloid leukemia (AML).
  • Between January 1996 and December 2005, 340 children with AML from 5 university hospitals in Korea received the BHAC-based or cytarabine-based chemotherapy, with or without hematopoietic stem cell transplantation.
  • In the present study, the clinical outcomes of the BHAC-based chemotherapy, consisting of BHAC, idarubicin, and 6-TG, are comparable to that of the cytarabine-based chemotherapy for childhood AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / analogs & derivatives. Cytarabine / therapeutic use. Idarubicin / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Thioguanine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Cytogenetics. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant. Infant, Newborn. Male. Republic of Korea. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacokinet. 2002;41(10):705-18 [12162758.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1740-7 [3465875.001]
  • [Cites] J Clin Pharmacol. 1988 Apr;28(4):356-62 [3164731.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7587-92 [2253209.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(1):23-9 [8174198.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):204-13 [8558199.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Semin Hematol. 1996 Oct;33(4 Suppl 3):24-9 [8916313.001]
  • [Cites] Int J Hematol. 1999 Jul;70(1):56-7 [10446497.001]
  • [Cites] Leukemia. 2005 Jun;19(6):965-70 [15830007.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2101-16 [16136167.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2054-62 [16136168.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2025-9 [16304569.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2030-42 [16304570.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2090-100 [16304571.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):1-25 [17222748.001]
  • [Cites] Leukemia. 2008 Feb;22(2):428-32 [17713551.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Cancer Res. 1977 Aug;37(8 Pt 1):2481-6 [872077.001]
  • [Cites] Cancer Res. 1983 Jul;43(7):3412-6 [6850647.001]
  • [Cites] Cancer. 1985 Oct 15;56(8):1913-7 [3861233.001]
  • [Cites] Cancer Res. 1976 Aug;36(8):2726-32 [1277182.001]
  • (PMID = 20052341.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 9YVR68W306 / enocitabine; FTK8U1GZNX / Thioguanine; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2800026
  • [Keywords] NOTNLM ; Childhood / Enocitabine / Leukemia, Myeloid, Acute
  •  go-up   go-down


22. Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W: Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol; 2009 Jan 1;27(1):61-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
  • PURPOSE: The purpose of the study was to assess the contribution of age and disease variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving varying intensive induction chemotherapy.
  • PATIENTS AND METHODS: Patients 16 to 85 years of age with primary AML, known karyotype, and uniform postremission chemotherapy enrolled onto two consecutive trials were eligible and were randomly assigned to induction either with a standard-dose (cytarabine, daunorubicin, and 6-thioguanine) and a high-dose (cytarabine and mitoxantrone) combination, or with two courses of the high-dose combination.
  • CONCLUSION: Under harmonized conditions, older and younger patients with AML show modest differences in their risk profiles and equally no dose response to intensified chemotherapy.
  • Further molecular investigation may elucidate the age effect in AML and identify new targets.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Multivariate Analysis. Mutation. Nuclear Proteins / genetics. Prognosis. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


23. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Löwenberg B, Delwel R: High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood; 2008 Apr 15;111(8):4329-37
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
  • Inappropriate expression of EVI1 (ecotropic virus integration-1), in particular splice form EVI1-1D, through chromosome 3q26 lesions or other mechanisms has been implicated in the development of high-risk acute myeloid leukemia (AML).
  • To validate the clinical relevance of EVI1-1D, as well as of the other EVI1 splice forms and the related MDS1/EVI1 (ME) gene, real-time quantitative polymerase chain reaction was performed in 534 untreated adults with de novo AML.
  • EVI1(+)ME(-) expression predicts an extremely poor prognosis distinguishable from the general EVI1(+) AML patients (overall survival [OS]: P < .001 and event-free survival [EFS]: P = .002).
  • We argue that EVI1/ME quantitative expression analysis should be implemented in the molecular diagnostic procedures of AML.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 3 / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / pathology. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adult. Aged. Alternative Splicing / genetics. Cohort Studies. Cytogenetic Analysis. Female. Gene Expression Regulation, Leukemic. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Multivariate Analysis. Prognosis. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18272813.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Transcription Factors
  •  go-up   go-down


24. Mi Y, Xue Y, Yu W, Liu S, Zhao Y, Meng Q, Bian S, Wang J: Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. Leuk Lymphoma; 2008 Mar;49(3):524-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
  • One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years.
  • We conclude that triple-drugs induction regimens based on HA (HAD/M) are highly effective in adult AML in China.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. China. Cytarabine / therapeutic use. Cytogenetic Analysis. Daunorubicin / therapeutic use. Female. Harringtonines / therapeutic use. Humans. Karyotyping. Male. Middle Aged. Mitoxantrone / therapeutic use. Prognosis. Remission Induction / methods. Retrospective Studies. Survival Analysis


25. Ersvaer E, Hampson P, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø: Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology; 2007 Jun;12(3):199-207
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex.
  • T lymphocyte defects may contribute to the immune insufficiency seen in acute myelogenous leukemia (AML).
  • We therefore characterized the T cell system for untreated AML patients.
  • T lymphocyte subsets were analyzed by flow cytometry for 45 AML patients.
  • The in vitro interferon-gamma (IFNgamma) release in response to stimulation with anti-CD3 plus anti-CD28 in the presence of autologous AML cells was examined for 31 patients.
  • The T cells could be stimulated to release IFNgamma in response to anti-CD3 plus anti-CD28 ligation even in the presence of excess autologous AML blasts, and for a subset of patients (6 of 27) these IFNgamma levels could be further increased by the novel protein kinase C (PKC) agonist PEP005.
  • In conclusion, circulating T cells in patients with untreated AML are mainly CD4(+) or CD8(+) TCRalphabeta(+); both CD45RA(+) and CD45R0(+) can be detected, and these cells can be activated through the CD3/TCR complex even in the presence of excess AML cells.
  • For a subset of patients T cell responsiveness can be further increased by targeting PKC and these data therefore suggest that T cell function is not inhibited in AML patients.
  • [MeSH-major] Antigens, CD3 / immunology. Leukemia, Myeloid, Acute / immunology. Lymphocyte Activation / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Cells. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Protein Kinase C. Receptors, Antigen, T-Cell / immunology. T-Lymphocyte Subsets / immunology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558695.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Receptors, Antigen, T-Cell; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


26. Hartmann U, Brümmendorf TH, Balabanov S, Thiede C, Illme T, Schaich M: Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica; 2005 Mar;90(3):307-16
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities.
  • BACKGROUND AND OBJECTIVES: Acute myeloid leukemia (AML) is a malignant, genetically heterogenous disorder characterized by uncontrolled growth of immature myeloid cells.
  • The aim of this study was to analyze whether telomere length and/or hTERT expression are correlated with clonal chromosomal aberrations in AML.
  • DESIGN AND METHODS: Telomere length in mononuclear cells derived from 137 previously untreated patients with >or= 80% blasts was analyzed by flow fluorescent in situ hybridization.
  • RESULTS: Age-adjusted telomere length in AML patients was significantly reduced as compared to in matched controls, consisting of peripheral blood granulocytes from healthy individuals (0-90 years) (median: -2.5 TFU; p<0.001).
  • INTERPRETATION AND CONCLUSIONS: These findings suggest an important role of intense telomere loss in the development of genetic instability during the pathogenesis of AML.
  • It is assumed that critical telomere shortening in AML blasts could lead to telomerase activation and therefore prevent blasts from replicative senescence, one possible mechanism for clonal selection and disease progression.
  • Therefore, telomere length might serve as a prognostic marker for AML patients.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid / genetics. Telomerase / genetics. Telomere / ultrastructure
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Case-Control Studies. Gene Expression Regulation, Neoplastic. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Mar;90(3):289B [15749652.001]
  • (PMID = 15749662.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


27. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM: Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood; 2006 Jul 1;108(1):45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
  • Outcome of patients with acute myeloid leukemia (AML) who are older than 60 years of age remains unsatisfactory, with low remission rates and poor overall survival.
  • We have previously established the activity of clofarabine plus cytarabine in AML relapse.
  • We have now conducted a phase 2 study of clofarabine plus cytarabine in patients aged 50 years or older with previously untreated AML.
  • Of 60 patients, 29 (48%) had secondary AML, 30 (50%) had abnormal karyotypes (monosomy 5 and/or 7 in 15 [25%]), and 11 (21%) showed FLT3 abnormalities.
  • Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate.
  • Modifications of this combination in AML therapy of older patients warrant further evaluation.
  • [MeSH-major] Adenine Nucleotides / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arabinonucleosides / administration & dosage. Cytarabine / administration & dosage. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Chromosome Aberrations. Drug Administration Schedule. Humans. Middle Aged. Remission Induction. Survival Rate. Treatment Outcome


28. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD, Mayo P2C Phase II Consortium: A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica; 2009 Oct;94(10):1375-82
Hazardous Substances Data Bank. Vorinostat .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of vorinostat in acute myeloid leukemia.
  • SAHA) in patients with relapsed acute myeloid leukemia and in selected untreated patients with high-risk acute myeloid leukemia.
  • DESIGN AND METHODS: Patients with relapsed or untreated acute myeloid leukemia who were not candidates for chemotherapy entered one of the two treatment arms.
  • CONCLUSIONS: Vorinostat monotherapy demonstrated minimal activity in this group of patients with acute myeloid leukemia.
  • Future studies of vorinostat in acute myeloid leukemia should focus on combinations with other drugs with which it might interact pharmacodynamically.
  • [MeSH-major] Hydroxamic Acids / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2001;3(2):122-33 [11250759.001]
  • [Cites] Mol Med. 2000 Oct;6(10):849-66 [11126200.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8 [11535817.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1321-30 [11696577.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):287-97 [11703323.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8492-7 [11731433.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):194-202 [11902574.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):963-70 [11948101.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1695-713 [12457432.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3236-9 [12446442.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2118-26 [12727828.001]
  • [Cites] Blood. 2003 May 15;101(10):4055-62 [12531799.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4460-71 [12907619.001]
  • [Cites] Curr Med Chem. 2003 Nov;10(22):2343-50 [14529477.001]
  • [Cites] Cancer Biol Ther. 2003 Sep-Oct;2(5):544-51 [14614324.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2896-905 [18660379.001]
  • [Cites] Cancer. 2008 Oct 1;113(7 Suppl):1933-52 [18798533.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1698-707 [19223502.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2580-9 [15059915.001]
  • [Cites] Ann Med. 2004;36(4):304-14 [15224657.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5705-8 [8650156.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2841-51 [8874180.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):103-13 [9045296.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7 [9501205.001]
  • [Cites] Annu Rev Biochem. 1998;67:545-79 [9759497.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4116-24 [10361108.001]
  • [Cites] Nature. 1999 Sep 9;401(6749):188-93 [10490031.001]
  • [Cites] Expert Opin Ther Targets. 2005 Aug;9(4):809-24 [16083344.001]
  • [Cites] J Invest Dermatol. 2005 Nov;125(5):1045-52 [16297208.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] Cancer J. 2007 Mar-Apr;13(2):80-3 [17476134.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1060-6 [17962510.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1886-93 [18591380.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):681-92 [10690554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 [10954755.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5165-70 [11016644.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2292-300 [11489804.001]
  • (PMID = 19794082.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00305773
  • [Grant] United States / NCI NIH HHS / CA / K24 CA111717; United States / NCI NIH HHS / CA / K24 CA111717-05; United States / NCI NIH HHS / CM / N01 CM17104
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Other-IDs] NLM/ PMC2754953
  •  go-up   go-down


29. Petersdorf SH, Rankin C, Head DR, Terebelo HR, Willman CL, Balcerzak SP, Karnad AB, Dakhil SR, Appelbaum FR: Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Am J Hematol; 2007 Dec;82(12):1056-62
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
  • Induction therapy for acute myeloid leukemia (AML) usually consists of 7 days of cytarabine at 100-200 mg/m(2)/day and an anthracycline.
  • Such combinations produce complete response (CR) rates of 60-80% in patients with de novo AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Ethnic Groups. Female. Humans. Male. Middle Aged. Survival Analysis. Time Factors. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696203.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA04920; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA28862; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63845; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA76429; United States / NCI NIH HHS / CA / CA76462
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


30. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE: A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood; 2007 Feb 15;109(4):1387-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
  • Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors.
  • In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML.
  • Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3631-52 [10550163.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7514-26 [10602510.001]
  • [Cites] Invest New Drugs. 1999;17(3):241-58 [10665477.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1268-74 [2475589.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2847-53 [1581898.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3229-32 [8205544.001]
  • [Cites] N Engl J Med. 1995 Jun 22;332(25):1671-7 [7760868.001]
  • [Cites] Blood. 1995 Jul 15;86(2):457-62 [7605984.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67 [10680081.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1871-7 [10766174.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2318-25 [10873082.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6105-13 [10913192.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30451-7 [10852915.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Exp Cell Res. 2001 Jan 1;262(1):17-27 [11120601.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):131-7 [11196150.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):450-8 [11809695.001]
  • [Cites] Blood. 2002 Jul 1;100(1):29-35 [12070004.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1224-32 [12149202.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3295-304 [7614464.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5302-9 [7585592.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):708-13 [9044849.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2969-77 [9376577.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Blood. 1998 May 15;91(10):3607-15 [9572995.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1439-45 [9779989.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1090-8 [16435386.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • (PMID = 17082323.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070095; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA70095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNAJA1 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / Quinolones; 192185-72-1 / tipifarnib; EC 2.5.1.29 / Farnesyltranstransferase
  • [Other-IDs] NLM/ PMC1794070
  •  go-up   go-down


31. Bagheri K, Alimoghadam K, Pourfathollah AA, Hassan ZM, Hajati J, Moazzeni SM: The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience. Pathol Oncol Res; 2009 Jun;15(2):257-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience.
  • Leukemic cells of patients with acute myeloid leukemia (AML) could be differentiated to DC-like cells possessing the ability of stimulating anti-leukemic immune response.
  • Despite obvious progress in DC-based immunotherapy, some discrepancies were reported in differentiation potential of AML blasts from all patients toward DC like cells.
  • The present study, as a local experience, was set up to generate DCs from AML blasts of various subtypes.
  • Leukemic Blasts from 16 Iranian AML patients were differentiated into functional DCs by culturing in the presence of rhGM-CSF, rhIL-4 and TNF-alpha for 8 days.
  • The morphology, expression of key surface molecules and allostimulatory activity of resultant DCs were compared with primary blasts and cultured but cytokine untreated control groups.
  • Neo-expression or upregulation of DC-associated markers were occurred during culturing period in cytokine treated cells compared with primary blasts and cultured but cytokine untreated control groups: CD1a (63.22% vs. 3.22% and 11.79%), CD83 (41.27% vs. 0.11% and 0.70%), CD40 (15.17% vs. 0.00% and 0.04%), CD80 (49.96 vs. 0.02% and 0.32%), CD86 (56.49% vs. 0.50% and 5.71%) and HLA-DR (52.52% vs. 14.32% and 2.49%) respectively.
  • The expression pattern of ACE in AML-DCs, blast cells and DCs derived from normal monocytes (7.93%, 1.28% and 74.97% respectively) confirmed the leukemic origin of DCs.
  • Our data confirmed the generation of sufficient AML-derived cells with the properties of DCs in all cases.
  • This potency of AML blasts, offers a useful route for active immunotherapy of AML patients.
  • [MeSH-major] Dendritic Cells / immunology. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adult. Antigen-Presenting Cells. Cell Differentiation. Cell Proliferation. Child. Child, Preschool. Female. Flow Cytometry. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Immunophenotyping. Interleukin-4 / pharmacology. Lymphocyte Activation. Male. Middle Aged. Peptidyl-Dipeptidase A / metabolism. Recombinant Proteins / pharmacology. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807213.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 3.4.15.1 / Peptidyl-Dipeptidase A
  •  go-up   go-down


32. Bow EJ, Meddings JB: Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia; 2006 Dec;20(12):2087-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia.
  • Intestinal barrier function was prospectively examined in the course of a clinical trial evaluating the efficacy and safety of lisofylline for reducing cytotoxic therapy-induced intestinal epithelial damage-related infectious morbidity in patients receiving standard remission-induction therapy for acute myeloid leukaemia.
  • The absorption and permeation of oral D-Xylose, lactulose and mannitol were measured weekly from baseline until marrow recovery in adult recipients of idarubicin plus cytarabine for untreated acute myeloid leukaemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Infection / etiology. Intestinal Mucosa / drug effects. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Intestinal Absorption / drug effects. Male. Middle Aged. Prospective Studies. Remission Induction. Xylose / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082779.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; A1TA934AKO / Xylose
  •  go-up   go-down


33. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA, Cancer and Leukemia Group B: P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood; 2010 Sep 02;116(9):1413-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
  • Cancer and Leukemia Group B 19808 (CALGB 19808) is the only randomized trial of a second-generation P-glycoprotein (Pgp) modulator in untreated patients with acute myeloid leukemia (AML) younger than age 60 years.
  • Inhibition of Pgp-mediated drug efflux by PSC-833 did not improve clinical outcomes in younger patients with untreated AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclosporins / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. P-Glycoprotein / antagonists & inhibitors
  • [MeSH-minor] Adolescent. Adult. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Remission Induction. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 May 1;105(9):3420-7 [15572587.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4614-22 [16484584.001]
  • [Cites] Blood. 2007 May 15;109(10):4168-70 [17227830.001]
  • [Cites] Leuk Lymphoma. 2007 Aug;48(8):1587-99 [17701591.001]
  • [Cites] Exp Hematol. 2007 Dec;35(12):1793-800 [17923246.001]
  • [Cites] Leuk Res. 2008 Mar;32(3):465-73 [17826829.001]
  • [Cites] Leuk Res. 2009 Aug;33(8):1055-61 [19108889.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3574-82 [19417029.001]
  • [Cites] Bone Marrow Transplant. 2009 Sep;44(6):353-9 [19289999.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] Blood. 2010 Jan 21;115(3):453-74 [19880497.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(1):50-7 [10707999.001]
  • [Cites] Blood. 2000 May 1;95(9):2897-904 [10779437.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2482-92 [11331327.001]
  • [Cites] Leuk Lymphoma. 2001 Feb;40(5-6):613-23 [11426533.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3212-20 [11719356.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1224-32 [12149202.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2812-9 [12231521.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1202-10 [12663440.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1078-86 [15020609.001]
  • [Cites] Haematologica. 2004 Jul;89(7):782-90 [15257929.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1940-51 [15217827.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1593-602 [7563202.001]
  • [Cites] Oncol Res. 1995;7(12):603-10 [8704277.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1796-802 [9164187.001]
  • [Cites] Leukemia. 1998 Feb;12(2):192-9 [9519781.001]
  • [Cites] Blood. 1999 Feb 1;93(3):787-95 [9920827.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4086-95 [10361105.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2646-54 [15994288.001]
  • (PMID = 20522709.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00006363
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / U10 CA003927
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclosporins; 0 / P-Glycoprotein; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q7ZP55KF3X / valspodar; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC2938834
  •  go-up   go-down


34. Li CW, Bo LJ, Dai Y, Liu XP, Qin S, Liu SH, Wang JX: [Application of dual-color fluorescence in situ hybridization in acute myeloid leukemia with t (8; 21)]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jan;27(1):32-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of dual-color fluorescence in situ hybridization in acute myeloid leukemia with t (8; 21)].
  • OBJECTIVE: To investigate the utilities of dual-color fluorescence in situ hybridization (FISH) in diagnosis and monitor of treatment in acute myeloid leukemia (AML) with t (8; 21).
  • METHODS: Seventy patients having FISH results were divided into two groups: untreated and treated group.
  • RESULTS: In untreated group, 30/42 cases of t (8;.
  • 21) AML were positive for AML1/ETO in FISH assay.
  • Three cases were positive for AML/ETO by FISH although two of them lacked t (8;.
  • 21) AML diagnosed.
  • 21) AML and minimal residual disease (MRD) monitoring.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Humans. Karyotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16732938.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Hussein K, Jahagirdar B, Gupta P, Burns L, Larsen K, Weisdorf D: Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia. Am J Hematol; 2008 Jun;83(6):446-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
  • We retrospectively analyzed 194 previously untreated acute myeloid leukemia (AML) patients to evaluate the role of Day 14 bone marrow (BM) biopsy in predicting complete remission (CR).
  • [MeSH-major] Blast Crisis / pathology. Leukemia, Myeloid, Acute / pathology. Predictive Value of Tests
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Examination. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18247382.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Jacobs P, Wood L: Clonogenic growth patterns correlate with chemotherapy response in acute myeloid leukaemia. Hematology; 2005 Aug;10(4):321-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonogenic growth patterns correlate with chemotherapy response in acute myeloid leukaemia.
  • Cytosine arabinoside and anthracycline-containing regimens induce remission in upwards of 60% of previously untreated patients with adult acute myeloid leukaemia (AML).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Leukemia, Myeloid, Acute / metabolism. Neoplastic Stem Cells / metabolism. Tumor Stem Cell Assay
  • [MeSH-minor] Adolescent. Adult. Cell Survival / drug effects. Cytarabine / therapeutic use. Female. Humans. Male. Middle Aged. Myeloid Progenitor Cells / metabolism. Myeloid Progenitor Cells / pathology. Pilot Projects. Predictive Value of Tests. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085545.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine
  •  go-up   go-down


37. Parkin B, Erba H, Ouillette P, Roulston D, Purkayastha A, Karp J, Talpaz M, Kujawski L, Shakhan S, Li C, Shedden K, Malek SN: Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood; 2010 Dec 2;116(23):4958-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.
  • Genomic aberrations are of predominant importance to the biology and clinical outcome of patients with acute myelogenous leukemia (AML), and conventional karyotype-based risk classifications are routinely used in clinical decision making in AML.
  • In this study, we analyzed flow cytometer-sorted, AML blast-derived, and paired, buccal DNA from 114 previously untreated prospectively enrolled AML patients for acquired genomic copy number changes and loss of heterozygosity using Affymetrix SNP 6.0 arrays, and we correlated genomic lesion load and specific chromosomal abnormalities with patient survival.
  • Finally, we identified an independent negative prognostic impact of p53 mutations, or p53 mutations and 17p-loss of heterozygosity combined on survival in AML.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):16-25 [15325089.001]
  • [Cites] Leukemia. 2010 Feb;24(2):438-49 [20016533.001]
  • [Cites] Am J Clin Pathol. 1993 Nov;100(5):534-40 [8249893.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3148-57 [7949187.001]
  • [Cites] Leukemia. 1994 Dec;8(12):2241-2 [7808014.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):375-8 [15695375.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9152-4 [16230371.001]
  • [Cites] Leukemia. 2006 May;20(5):840-6 [16498392.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Leukemia. 2000 Mar;14(3):513-7 [10720153.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1405-13 [11230485.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Jul 1;102(1):43-52 [12623843.001]
  • [Cites] Leukemia. 2004 Jan;18(1):120-5 [14586477.001]
  • [Cites] Leukemia. 2004 Feb;18(2):293-302 [14671635.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3887-94 [16864856.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1224-31 [17377590.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4777-85 [17699855.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3365-73 [17634407.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1534-42 [17954704.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1584-93 [17971485.001]
  • [Cites] Leukemia. 2008 Feb;22(2):240-8 [18200041.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1012-21 [18281475.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] BMC Bioinformatics. 2010;11:74 [20132550.001]
  • [Cites] Nature. 2010 Apr 1;464(7289):704-12 [19812545.001]
  • [Cites] Blood. 2010 Jul 8;116(1):71-80 [20404136.001]
  • [Cites] Clin Cancer Res. 2010 Aug 15;16(16):4135-47 [20505189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]
  • [Cites] Leukemia. 2008 May;22(5):915-31 [18288131.001]
  • [Cites] Blood. 2008 Aug 1;112(3):814-21 [18490517.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1539-41 [18528419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11921-6 [18697940.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1993-2003 [18436738.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4791-7 [18695255.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10349-57 [19074904.001]
  • [Cites] Leukemia. 2009 Jan;23(1):203-6 [18596741.001]
  • [Cites] Leukemia. 2009 Apr;23(4):656-63 [19151774.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2289-301 [19474426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12950-5 [19651600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12944-9 [19651601.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5219-26 [19770377.001]
  • [Cites] Blood. 1989 Jan;73(1):263-70 [2910364.001]
  • (PMID = 20729466.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / R01 CA136537; United States / NCI NIH HHS / CA / 1R01 CA136537-01; United States / NCI NIH HHS / CA / 5 P30 CA46592
  • [Publication-type] Historical Article; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC3012590
  •  go-up   go-down


38. Teng CL, Young JH, Hsu SL, Chou G, Kuo IT, Yu CY, Hwang GY: Lactate dehydrogenase, not vascular endothelial growth factor or basic fibroblast growth factor, positively correlates to bone marrow vascularity in acute myeloid leukemia. J Chin Med Assoc; 2006 Nov;69(11):534-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lactate dehydrogenase, not vascular endothelial growth factor or basic fibroblast growth factor, positively correlates to bone marrow vascularity in acute myeloid leukemia.
  • BACKGROUND: Angiogenesis has been extensively studied in acute myeloid leukemia (AML).
  • Lactate dehydrogenase (LDH), a common biochemical marker for tumor burden and anaerobic glycolysis, is a poor prognostic factor for AML.
  • To study the roles of serum LDH, VEGF and bFGF in AML angiogenesis, we investigated bone marrow vascularity in untreated AML patients, and analyzed its relationship to serum LDH, VEGF and bFGF levels.
  • METHODS: Eighteen (11 males, 7 females; mean age, 57.7 years) de novo, untreated AML patients were enrolled.
  • RESULTS: Log LDH significantly correlated to AML bone marrow vascularity (r = 0.61; p = 0.007).
  • VEGF and bFGF concentrations did not correlate with AML angiogenesis.
  • CONCLUSION: These results suggest that serum LDH, but not VEGF and bFGF concentrations, can be used as a simple parameter for predicting vessel formation in AML bone marrow.
  • [MeSH-major] Bone Marrow / blood supply. Fibroblast Growth Factor 2 / blood. L-Lactate Dehydrogenase / blood. Leukemia, Myeloid, Acute / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116616.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


39. Fiegl M, Zimmermann I, Lorenz I, Hiddemann W, Braess J: In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia. Ann Hematol; 2008 Jan;87(1):27-33
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia.
  • Only about one third of all patients with acute myeloid leukemia (AML) will be cured by common chemotherapy regimens.
  • We determined the lethal concentration of chemotherapy necessary to reduce viability of cells to 50% compared to untreated control (LC50) as a surrogate marker of chemotherapy susceptibility of six established chemotherapeutic agents [cytarabine (median 0.83 microg/ml), daunorubicine (0.09 microg/ml), idarubicine (0.03 microg/ml), mitoxantrone (0.05 microg/ml), etoposide (4.81 microg/ml), and topotecan (0.14 microg/ml)] in an overall number of 147 samples from consecutive patients with AML by WST-1 assay in vitro.
  • These data indicate that cross-resistance in AML against antileukemic drugs exists between agents with different modes of action and seems not to be mediated by drug-specific resistance mechanisms but rather by more generalized death-defying features of the affected cells (e.g., inhibited apoptosis).
  • [MeSH-major] Drug Resistance, Neoplasm / drug effects. Enzyme Inhibitors / pharmacology. Leukemia, Myeloid, Acute / enzymology. Nucleosides / pharmacology. Topoisomerase I Inhibitors. Topoisomerase II Inhibitors
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Survival / drug effects. DNA Topoisomerases, Type I / metabolism. DNA Topoisomerases, Type II / metabolism. Female. Humans. Male. Middle Aged. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710400.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Nucleosides; 0 / Topoisomerase I Inhibitors; 0 / Topoisomerase II Inhibitors; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


40. Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T: Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res; 2005 Feb 15;11(4):1416-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
  • PURPOSE: The recognition of a number of leukemia-specific cytogenetic abnormalities and their role as independent prognostic factors have provided considerable insights into leukemia pathogenesis and have paved the way to adopt risk-adapted treatment.
  • However, approximately 50% of newly diagnosed acute myeloid leukemia (AML) have a normal karyotype.
  • There has therefore been much interest in identifying molecular markers that could help to improve the prognostic stratification of patients with normal-karyotype AML.
  • EXPERIMENTAL DESIGN: Consecutive untreated AML patients (n = 67) from a single institution all with normal karyotype were analyzed for the presence of mutations in the myeloid transcription factor gene CEBPA (for CCAAT/enhancer binding protein-alpha), for internal tandem duplications (ITD) of the tyrosine kinase receptor gene FLT3 (for fms-like tyrosine kinase 3), and for expression of the BAALC gene (for brain and acute leukemia, cytoplasmic).
  • RESULTS: 17.9% of normal-karyotype AML had mutations in the CEBPA gene, and 28.4% had FLT3-ITD; 65.7% (44 of 67) had high BAALC expression and 34.3% (23 of 67) had low BAALC expression.
  • AML patients with FLT3-ITD had significantly shorter median DFS (P = 0.0328) and OS (P = 0.0148) than patients without FLT3-ITD.
  • High BAALC expression predicted for a shorter DFS (P = 0.0152) and OS (P = 0.0210) compared with AML with low BAALC expression; 53.7% of normal-karyotype AML had neither FLT3-ITD nor CEBPA mutations.
  • We found that high BAALC expression in normal-karyotype AML with neither FLT3-ITD nor CEBPA mutations (18 of 67) indicates adverse prognosis for both DFS and OS (P = 0.0001; e.g., P = 0.0001) compared with the group with low BAALC expression and absent FLT3-ITD and CEBPA mutations (18 of 67).
  • Thus, BAALC expression represents a novel prognostic marker particularly for normal-karyotype AML patients with neither FLT3-ITD nor CEBPA mutations.
  • CONCLUSIONS: Assessment of CEBPA mutations, FLT3-ITD, and BAALC expression permits to split normal-karyotype AML into clinically distinct subgroups.
  • [MeSH-major] Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antigens, CD / analysis. CCAAT-Enhancer-Binding Protein-alpha / genetics. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Immunophenotyping. Karyotyping. Male. Middle Aged. Mutation. Neoplasm Proteins / genetics. Prognosis. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics. Risk Assessment / methods. Survival Analysis. fms-Like Tyrosine Kinase 3

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2005 Aug 1;11(15):5659
  • (PMID = 15746041.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / BAALC protein, human; 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


41. Ruan GR, Li JL, Qin YZ, Li LD, Xie M, Chang Y, Zhang Y, Liu YR, Jiang B, Chen SS, Huang XJ: Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. Ann Hematol; 2009 Feb;88(2):159-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia.
  • Recently, mutations in the nucleophosmin (NPM1) gene were detected in 50-60% of adult acute myelogenous leukemia (AML) patients, mainly with a normal karyotype.
  • In this study, we detected typical NPM1 mutations (types A, B, D) in untreated Chinese AML patients using real-time quantitative polymerase chain reaction (RQ-PCR) followed by sequence analysis.
  • The detection rate of NPM1 mutations in 220 AML patients was 16.4%, including 107 (14.2%) with the French-American-British (FAB) subtype M2, 43 (2.3%) with M3, and 52 (30.8%) with M4/M5.
  • The results demonstrated that RQ-PCR was a reliable and sensitive method for detecting NPM1 mutations, for screening AML, and for the quantitative analysis of minimal residual diseases.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. China / epidemiology. Female. Follow-Up Studies. Gene Dosage / genetics. Humans. Indicator Dilution Techniques. Male. Middle Aged. Mutation / genetics. Plasmids / genetics. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726096.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


42. Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau JL, Löwenberg B, Stone RM, De Porre P, Wang Y, Karp JE: A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood; 2008 Mar 1;111(5):2589-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
  • We analyzed gene expression profiles from the bone marrow of patients from a phase 2 study of the FTI tipifarnib in older adults with previously untreated acute myeloid leukemia (AML).
  • The utility of this classifier for predicting response to tipifarnib was validated in an independent set of 58 samples from relapsed or refractory AML, with a negative predictive value (NPV) and positive predictive value (PPV) of 92% and 28%, respectively (odds ratio of 4.4).
  • Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib.
  • [MeSH-major] Farnesyltranstransferase / antagonists & inhibitors. Gene Expression Profiling. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Quinolones / pharmacology. Quinolones / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Female. Gene Expression Regulation, Leukemic / drug effects. Guanine Nucleotide Exchange Factors / genetics. Guanine Nucleotide Exchange Factors / metabolism. Humans. Male. Middle Aged. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Prognosis. Proportional Hazards Models. Recurrence. Reproducibility of Results. Survival Analysis


43. Mi YC, Xue YP, Yu WJ, Liu SH, Zhao YZ, Meng QX, Bian SG, Wang JX: [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype]. Zhonghua Xue Ye Xue Za Zhi; 2005 Dec;26(12):705-9
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
  • OBJECTIVE: To analyze the complete remission (CR) rate, disease free survival (DFS) and overall survival (OS) of de novo acute myeloid leukemia (AML) patients treated with HA based three drugs induction chemotherapy and to explore the impact of cytogenetic abnormalities on the prognosis.
  • METHODS: Two hundred and forty-three untreated de novo AML patients were treated with HA based three drugs induction therapy.
  • Cytogenetics is the important prognostic factor for AML patients and SWOG karyotype subtyping criteria is more appropriate than that of MRC, the differences among the three groups being statistically significant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cytarabine / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Harringtonines / administration & dosage. Humans. Karyotyping. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620570.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Harringtonines; 04079A1RDZ / Cytarabine
  •  go-up   go-down


44. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL: Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood; 2005 Jun 15;105(12):4576-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
  • The incidence of treatment-related myelodysplastic syndromes and acute myeloid leukemia (tMDSs/tAML) after tositumomab and iodine I(131) tositumomab administration to previously treated and untreated patients with non-Hodgkin lymphoma (NHL) was evaluated.
  • A total of 1071 patients were enrolled in 7 studies: 995 with relapsed/refractory low-grade NHL, +/- transformation (median, 3 prior regimens [range, 1-13 regimens]) and 76 patients with previously untreated low-grade follicular NHL.
  • Median follow-up was 6 years from diagnosis and 2 years from radioimmunotherapy (RIT) for previously treated patients, and 4.6 years from radioimmunotherapy for previously untreated patients. tMDS/tAML was reported in 35 (3.5%) of 995 patients (annualized incidence, 1.6%/y [95% confidence interval, 1.0%-2.0%/y]), and 52% of the tMDS/tAML diagnoses of tMDS/tAML were confirmed in a blinded review (annualized incidence of 1.1%/y [95% confidence interval, 0.7%-1.6%/y]).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / adverse effects. Iodine Radioisotopes / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Myelodysplastic Syndromes / chemically induced. Myelodysplastic Syndromes / diagnosis. Radioimmunotherapy / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials as Topic. Disease-Free Survival. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Models, Statistical. Radiometry. Remission Induction. Time Factors. Whole-Body Irradiation


45. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G: Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol; 2007 Sep 1;25(25):3884-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
  • PURPOSE: To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML).
  • PATIENTS AND METHODS: Twenty-five patients (median age, 70 years) were enrolled; 12 were untreated and 13 had relapsed AML.
  • In untreated AML, four of nine assessable patients achieved CR.
  • CONCLUSION: Low-dose decitabine was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Azacitidine / analogs & derivatives. Brain Diseases / chemically induced. Leukemia, Myeloid, Acute / drug therapy. Valproic Acid / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Fatigue / chemically induced. Humans. Infection / chemically induced. Maximum Tolerated Dose. Middle Aged. Neutropenia / chemically induced. Remission Induction. Treatment Failure

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679729.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00079378
  • [Grant] United States / NCI NIH HHS / CA / K23CA120708; United States / NCI NIH HHS / CA / R01 CA102031; United States / NCI NIH HHS / CA / U01 CA 76576
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 614OI1Z5WI / Valproic Acid; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


46. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood; 2007 Oct 1;110(7):2302-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
  • We conducted a phase 1/2 study of the combination of 5-azacitidine (5-AZA), valproic acid (VPA), and ATRA in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
  • In previously untreated older patients, the response rate was 52%.
  • [MeSH-major] Azacitidine / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Tretinoin / therapeutic use. Valproic Acid / therapeutic use
  • [MeSH-minor] Acetylation. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. DNA Methylation. Dose-Response Relationship, Drug. Drug Therapy, Combination. Drug-Related Side Effects and Adverse Reactions. Gene Expression Regulation. Histones / metabolism. Humans. Middle Aged. RNA, Messenger / genetics


47. Miyawaki S, Emi N, Mitani K, Oyashiki K, Kitamura K, Morishita T, Ogawa H, Komatsu N, Soma T, Tamaki T, Kosugi H, Ohnishi K, Mizoguchi H, Hiraoka A, Kodera Y, Ueda R, Morishima Y, Nakagawa M, Tobita T, Sugimoto K, Chiba S, Inoue N, Hamaguchi M, Koga D, Tamaki H, Naoe T, Sugiyama H, Takaku F: [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan]. Rinsho Ketsueki; 2005 Dec;46(12):1279-87
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
  • We evaluated the clinical course of acute myeloid leukemia (AML) and the levels of WT1 mRNA in 191 AML patients.
  • Of 114 previously untreated patients with AML, 107 cases were positive for WT1 mRNA (93.9% : 107/114).
  • Given the percent of the correct diagnosis, WT1 mRNA at 200 copies/microg RNA appeared to be a reasonable cut-off level for early detection of AML-relapse.
  • Besides these promising data, this kit is suitable for routine monitoring of AML because this kit utilizes peripheral blood as a test specimen, reducing the patient's burden at the time of collection of clinical samples as compared with bone marrow aspirate.
  • [MeSH-major] Biomarkers, Tumor / blood. Leukemia, Myeloid, Acute / diagnosis. RNA, Messenger / blood. RNA, Neoplasm / blood. WT1 Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Early Diagnosis. Female. Humans. Japan. Male. Middle Aged. Monitoring, Physiologic / methods. Neoplasm Recurrence, Local / diagnosis. Neoplasm, Residual / diagnosis. Polymerase Chain Reaction / methods. Reagent Kits, Diagnostic

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447800.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Reagent Kits, Diagnostic; 0 / WT1 Proteins
  •  go-up   go-down


48. Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Buchner T, Neubauer A, Fauser AA, Ehninger G, Berdel WE, Kienast J, Cooperative German Transplant Study Group: Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood; 2005 Nov 1;106(9):3314-21
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
  • Seventy-one patients with acute myeloid leukemia (AML), most of them (63/71) considered ineligible for conventional allogeneic hematopoietic stem cell transplantation (HSCT), were enrolled into a phase 2 study on reduced-intensity myeloablative conditioning with fractionated 8-Gy total body irradiation (TBI) and fludarabine (120 mg/m2).
  • Thirty-six patients received a transplant in complete remission (CR) and 35 had untreated or refractory disease (non-CR).
  • Outcome data in this poor-risk population indicate that allogeneic HSCT from related or unrelated donors with 8-Gy TBI/fludarabine conditioning is feasible with low NRM and preserved antileukemic activity in AML patients in first or later CR.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / radiotherapy. Transplantation Conditioning / methods. Vidarabine / analogs & derivatives. Whole-Body Irradiation
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome


49. Xiao L, Huang Y, Zhen R, Chiao JW, Liu D, Ma X: Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol; 2010;123(2):71-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate.
  • OBJECTIVE: Since histone hypoacetylation due to excess histone deacetylases (HDACs) has been associated with transcriptional repression in leukemia, we aimed to determine deficient histone acetylation in patients with acute leukemia and the effect of its correction by an isothiocyanate.
  • METHODS: The acetylation status of histones H3 and H4 in cells from patients with untreated acute leukemia was determined by Western blot.
  • Bone marrow cells from 10 patients with acute myeloid leukemia (AML) were cultured in phenylhexyl isothiocyanate (PHI) to evaluate correction of the deficiency.
  • RESULTS: Acetylation of histones H3 and H4 was virtually undetectable or significantly lower in acute leukemia.
  • Histone acetylation was up-regulated in the presence of PHI, revealing an excess of deacetylation activity in AML.
  • CONCLUSIONS: Deficient histone acetylation may represent an aberration at the epigenetic level in acute leukemia.
  • PHI might represent a target for correcting deficient acetylation, and potential epigenetic regulators for preventing the progression of leukemia.
  • [MeSH-major] Histones / metabolism. Isothiocyanates / therapeutic use. Leukemia, Myeloid, Acute / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Acetylation. Adult. Aged. Child. Child, Preschool. Female. Histone Deacetylases / metabolism. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 20051681.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Histones; 0 / Isothiocyanates; 133920-06-6 / 6-phenylhexyl isothiocyanate; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


50. Qian SX, Li JY, Hong M, Lu H, Wu HX, Qiu HX, Zhang SJ, Chen LJ, Xu W, Sheng RL: [Efficacy of IA regimen followed by FLAG regimen in the treatment of acute myeloid leukaemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jan;30(1):22-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of IA regimen followed by FLAG regimen in the treatment of acute myeloid leukaemia].
  • OBJECTIVE: To investigate the efficacy and toxicity of standard-dose IA regimen (idarubicin and cytarabine) as induction therapy followed by FLAG regimen in patients with acute myeloid leukemia (AML), and its influence on peripheral stem cell mobilization.
  • METHODS: A total of 23 previously untreated de novo AML patients were enrolled.
  • CONCLUSION: IA followed by FLAG regimen is effective and well tolerable in AML patients especially in those with favourable and intermediate prognostic karyotypes, and 1 to 2 courses of this therapy shows no influence on peripheral stem cell mobilization and subsequent autologous stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563030.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


51. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM: Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol; 2010 Apr 10;28(11):1856-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
  • PURPOSE To determine the efficacy and toxicity of the combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia (AML) younger than age 65 years.
  • PATIENTS AND METHODS In the phase I part of the study, 10 patients with relapsed AML were treated with escalating doses of sorafenib with chemotherapy to establish the feasibility of the combination.
  • We then treated 51 patients (median age, 53 years; range, 18 to 65 years) who had previously untreated AML with cytarabine at 1.5 g/m(2) by continuous intravenous (IV) infusion daily for 4 days (3 days if > 60 years of age), idarubicin at 12 mg/m(2) IV daily for 3 days, and sorafenib at 400 mg orally twice daily for 7 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Benzenesulfonates / administration & dosage. Cytarabine / administration & dosage. Feasibility Studies. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Mutation / genetics. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / administration & dosage. Survival Rate. Treatment Outcome. Young Adult. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2009 Jun 25;113(26):6567-71 [19389879.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3938-46 [19029442.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):983-8 [11442493.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):413-5 [12124170.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2269-78 [12369855.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4372-80 [12393388.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):535-50 [12576416.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):650-65 [12951584.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1738-52 [12970773.001]
  • [Cites] Blood. 2004 Jan 1;103(1):267-74 [12969963.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2266-75 [14604974.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1841-9 [15166029.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1855-8 [15178581.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2584-93 [1384791.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1089-96 [8562934.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4202-9 [15304385.001]
  • [Cites] Blood. 2005 Jan 1;105(1):335-40 [15345593.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] Blood. 2005 Jan 1;105(1):22-30 [15358622.001]
  • [Cites] Blood. 2005 May 1;105(9):3679-85 [15626738.001]
  • [Cites] Blood. 2006 Jan 1;107(1):293-300 [16150941.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1090-8 [16435386.001]
  • [Cites] Blood. 2006 May 1;107(9):3700-7 [16410449.001]
  • [Cites] Blood. 2006 Jul 1;108(1):405-6; author reply 406 [16790588.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2074-6 [16990788.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3262-70 [16857985.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3477-83 [16857987.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3494-503 [16868253.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3674-81 [16902153.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:178-84 [17124058.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1643-52 [17047150.001]
  • [Cites] Leuk Res. 2007 Jun;31(6):791-7 [17156841.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1262-70 [17456725.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3547-51 [17673605.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4476-9 [17827387.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1552-9 [17940205.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 6;100(3):184-98 [18230792.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2776-84 [17957027.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2527-37 [17965322.001]
  • [Cites] Leukemia. 2008 Apr;22(4):808-18 [18200035.001]
  • [Cites] Blood. 2008 Jul 15;112(2):444-5; author reply 445 [18606888.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2246-55 [19052971.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):624-31 [10698507.001]
  • (PMID = 20212254.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA100632; United States / NCI NIH HHS / CA / R01 CA128864; United States / NCI NIH HHS / CA / R01 CA128864-04
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 04079A1RDZ / Cytarabine; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2930809
  •  go-up   go-down


52. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD: Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol; 2009 Jul 1;27(19):3198-204
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
  • PURPOSE To determine the prognostic importance of the meningioma 1 (MN1) gene expression levels in the context of other predictive molecular markers, and to derive MN1 associated gene- and microRNA-expression profiles in cytogenetically normal acute myeloid leukemia (CN-AML).
  • PATIENTS AND METHODS MN1 expression was measured in 119 untreated primary CN-AML adults younger than 60 years by real-time reverse-transcriptase polymerase chain reaction.
  • Patients were intensively treated on two first-line Cancer and Leukemia Group B clinical trials.
  • CONCLUSION MN1 expression independently predicts outcome in CN-AML patients.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1511-9 [7731705.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1418-25 [8640834.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2234-44 [15890672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3740-6 [16051734.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3747-54 [16109776.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1582-92 [16810199.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3898-905 [16912223.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5164-7 [17341662.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1679-90 [17525718.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3337-43 [17577018.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1639-47 [17494859.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19849-54 [18056638.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1552-9 [17940205.001]
  • [Cites] J Mol Med (Berl). 2008 Mar;86(3):313-22 [18193184.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):239-44 [18636143.001]
  • [Cites] Nat Rev Immunol. 2008 Aug;8(8):607-18 [18641646.001]
  • [Cites] Dev Cell. 2008 Aug;15(2):261-71 [18694565.001]
  • [Cites] Dev Cell. 2008 Aug;15(2):272-84 [18694566.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Nat Genet. 2002 May;31(1):19-20 [11984561.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Oncogene. 2003 Feb 6;22(5):699-709 [12569362.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • (PMID = 19451432.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U24 CA114725; United States / NCI NIH HHS / CA / U10 CA101140; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / U10 CA003927
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAALC protein, human; 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / ERG protein, human; 0 / MLL protein, human; 0 / MN1 protein, human; 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Trans-Activators; 0 / Tumor Suppressor Proteins; 117896-08-9 / nucleophosmin; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2716941
  •  go-up   go-down


53. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer; 2009 Jan 1;115(1):101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
  • BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children.
  • RESULTS: Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients).
  • Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients.
  • Secondary AML/MDS developed at a median of 32 months after ALL diagnosis.
  • Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS.
  • Response to treatment was complete remission in 3 patients, partial remission in 6 patients, and no response in 6 patients; 1 patient was untreated.
  • Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation.
  • The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months).
  • CONCLUSIONS: Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Middle Aged. Vincristine / administration & dosage


54. Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA: Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood; 2005 May 1;105(9):3420-7
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
  • The Cancer and Leukemia Group B (CALGB) study 9222 tested the hypothesis that treatment intensification of acute myeloid leukemia (AML) in first remission with multiple chemotherapy agents is superior to high-dose cytarabine (HiDAC) alone.
  • We enrolled 474 patients younger than 60 years old with untreated de novo AML.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4116-24 [10361108.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1224-32 [12149202.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1087-94 [15020610.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Cancer Treat Rep. 1982 Jan;66(1):37-42 [7053264.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] J Clin Oncol. 1985 Dec;3(12):1583-9 [3906048.001]
  • [Cites] Control Clin Trials. 1987 Mar;8(1):67-74 [3568698.001]
  • [Cites] Leukemia. 1990 Mar;4(3):189-92 [2314118.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Blood. 1990 Aug 1;76(3):473-9 [2378980.001]
  • [Cites] Am J Hematol. 1990 Oct;35(2):80-3 [2399909.001]
  • [Cites] Am J Clin Oncol. 1990 Dec;13(6):516-9 [2239806.001]
  • [Cites] JAMA. 1993 Jul 28;270(4):459-64 [8320783.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Blood. 1995 Jul 15;86(2):457-62 [7605984.001]
  • [Cites] Blood. 1997 Feb 1;89(3):780-8 [9028308.001]
  • [Cites] Lancet. 1998 Mar 7;351(9104):700-8 [9504514.001]
  • [Cites] Leukemia. 1998 Feb;12(2):139-43 [9519774.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4173-9 [9751631.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1059-73 [11571716.001]
  • (PMID = 15572587.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA0796; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47555; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA16450; United States / PHS HHS / / 33601; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA21060; United States / PHS HHS / / 31946; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA12449; United States / NCI NIH HHS / CA / CA37135; United States / PHS HHS / / 101140; United States / PHS HHS / / 16058; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA47545
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine
  • [Other-IDs] NLM/ PMC1895015
  •  go-up   go-down


55. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol; 2008 Nov 1;26(31):5078-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
  • PURPOSE: To evaluate the prognostic significance of CEBPA mutations in the context of established molecular markers in cytogenetically normal (CN) acute myeloid leukemia (AML) and gain biologic insights into leukemogenesis of the CN-AML molecular high-risk subset (FLT3 internal tandem duplication [ITD] positive and/or NPM1 wild type) that has a significantly higher incidence of CEBPA mutations than the molecular low-risk subset (FLT3-ITD negative and NPM1 mutated).
  • PATIENTS AND METHODS: One hundred seventy-five adults age less than 60 years with untreated primary CN-AML were screened before treatment for CEBPA, FLT3, MLL, WT1, and NPM1 mutations and BAALC and ERG expression levels.
  • Gene and microRNA (miRNA) expression profiles were obtained for the CN-AML molecular high-risk patients.
  • Among patients with CEBPA mutations, 91% were in the CN-AML molecular high-risk group.
  • CONCLUSION: Pretreatment testing for CEBPA mutations identifies CN-AML patients with different outcomes, particularly in the molecular high-risk group, thus improving molecular risk-based classification of this large cytogenetic subset of AML.
  • The gene and miRNA expression profiling provided insights into leukemogenesis of the CN-AML molecular high-risk group, indicating that CEBPA mutations are associated with partial erythroid differentiation.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Feb 15;99(4):1332-40 [11830484.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3770-81 [12110589.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2717-23 [12351377.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4372-80 [12393388.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2206-14 [12406909.001]
  • [Cites] Hematol J. 2003;4(1):31-40 [12692518.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] Immunity. 2003 Sep;19(3):451-62 [14499119.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):394-400 [15122210.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1418-25 [8640834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8705-10 [10411939.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1372-9 [15746035.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1416-24 [15746041.001]
  • [Cites] Blood. 2005 Jul 15;106(2):673-80 [15797998.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3618-20 [16046528.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3740-6 [16051734.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3733-9 [16076867.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6338-43 [16606850.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):203-8 [16755214.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Blood. 2007 Jan 1;109(1):389-90 [17190859.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):551-64 [17379065.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5164-7 [17341662.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2493-4; author reply 2494-5 [17557966.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3337-43 [17577018.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6766-76 [17934484.001]
  • [Cites] Nucleic Acids Symp Ser (Oxf). 2007;(51):415-6 [18029763.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):51-60 [17994017.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1552-9 [17940205.001]
  • [Cites] Leukemia. 2008 Mar;22(3):655-7 [17851556.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):263-70 [11242107.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [CommentIn] J Clin Oncol. 2009 Apr 20;27(12):2105; author reply 2106 [19273693.001]
  • [ErratumIn] J Clin Oncol. 2008 Dec 20;26(36):6021
  • (PMID = 18809607.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA09512; United States / NCI NIH HHS / CA / CA089341; United States / NCI NIH HHS / CA / CA96887; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA98933; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA90469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAALC protein, human; 0 / Biomarkers, Tumor; 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / ERG protein, human; 0 / MLL protein, human; 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Trans-Activators; 0 / WT1 Proteins; 117896-08-9 / nucleophosmin; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2652095
  •  go-up   go-down


56. Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L: A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma; 2010 Feb;51(2):252-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
  • In this randomized phase I study, eligible patients had relapsed/refractory acute myeloid leukemia (AML), and one prior induction regimen, or were age >65 with untreated myelodysplastic syndrome (MDS) or secondary AML.
  • One CR was seen in a patient with AML with FLT3-ITD.
  • The recommended phase II dose in AML is 300 mg BID continuously, and testing in combination and in FLT3-ITD AML is warranted.
  • [MeSH-major] Benzenesulfonates / therapeutic use. Leukemia, Myeloid / drug therapy. Myelodysplastic Syndromes / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Abdominal Pain / chemically induced. Acute Disease. Adult. Aged. Aged, 80 and over. Area Under Curve. Diarrhea / chemically induced. Dose-Response Relationship, Drug. Drug Administration Schedule. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Humans. Male. Metabolic Clearance Rate. Middle Aged. Nausea / chemically induced. Niacinamide / analogs & derivatives. Phenylurea Compounds. Phosphorylation / drug effects. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / pharmacokinetics. Protein Kinase Inhibitors / therapeutic use. Treatment Outcome


57. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S: Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant; 2005 Feb;11(2):108-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
  • Allogeneic progenitor cell transplantation is the only curative therapy for patients with refractory acute myelogenous leukemia or myelodysplastic syndromes.
  • Patients were selected if they had undergone an allogeneic transplantation between January 1988 and January 2002 and were not in remission or first untreated relapse at the time of transplantation.
  • These data support the use of allogeneic transplantation for patients with relapsed or refractory acute myelogenous leukemia/myelodysplastic syndromes and suggest that optimal immune suppression early after transplantation is essential for long-term survival even in patients with refractory myeloid leukemias.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous. Treatment Outcome


58. Xu RR, Liu K, Wang XL: [Study on the effect of Yiqi Yangyin Recipe and its different assembling on expressions of Flt3 and N-ras in acute myeloid leukemic cells]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Jun;30(6):575-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the effect of Yiqi Yangyin Recipe and its different assembling on expressions of Flt3 and N-ras in acute myeloid leukemic cells].
  • OBJECTIVE: To study the action mechanism of Yiqi Yangyin Recipe (YYR) in treating leukemia by observing the effects of YYR and its different assembling, energy supporting part (P1) and evil dispelling part (P2) on expressions of Flt3 and N-ras gene in acute myeloid leukemic (AML) cells.
  • METHODS: The mononuclear cells collected from bone marrow of 60 AML patients were assigned to four groups: the blank was untreated for control and the three tested groups were treated with YYR, P1 and P2, respectively.
  • CONCLUSION: YYR can inhibit the colonic proliferation of AML cells, decrease the expressions of FLT3 and N-ras in cells, therefore shows a therapeutic effect on AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20815269.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / yiqi yangyin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


59. Mazur G, Wróbel T, Butrym A, Kapelko-Słowik K, Poreba R, Kuliczkowski K: Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia. Neoplasma; 2007;54(4):285-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia.
  • Acute myeloid leukaemia (AML) is an aggressive malignancy with accumulation of blasts in bone marrow.
  • The aim of the study was to evaluate plasma level of CCL2 in patients with AML.
  • Plasma samples from 65 adult patients with AML taken before chemotherapy and in complete remission were measured by enzyme linked immunoassay to evaluate CCL2 levels.
  • In AML patients mean baseline CCL2 level (+/- SEM standard error of measurement) was significantly higher than in normal control: 365,26 +/- 5,62 pg/ml vs 265,56 +/- 5,48 pg/ml respectively (p<0.01).
  • We demonstrate increased mean CCL2 plasma level in untreated patients with AML.
  • Significantly lower plasma level of CCL2 was observed in patients with M4 and M5 AML subtypes according to FAB classification.
  • In AML group chemotherapy did not reduce CCL2 plasma level.
  • [MeSH-major] Chemokine CCL2 / blood. Leukemia, Myeloid / blood
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822317.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Chemokine CCL2
  •  go-up   go-down


60. Bernimoulin M, Stern M, Tichelli A, Jotterand M, Gratwohl A, Nissen C: Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome. Acta Haematol; 2008;119(4):226-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome.
  • In patients with myelodysplastic syndrome (MDS) precursor cell cultures (colony-forming unit cells, CFU-C) can provide an insight into the growth potential of malignant myeloid cells.
  • In a retrospective single-center study of 73 untreated MDS patients we assessed whether CFU-C growth patterns were of prognostic value in addition to established criteria.
  • In a univariate analysis the presence of leukemic growth was associated with strongly reduced survival (at 10 years 4 vs. 34%, p = 0.004), and a high incidence of transformation to AML (76 vs. 32%, p = 0.01).
  • Multivariate analysis identified leukemic growth as a strong and independent predictor of early death (relative risk 2.12, p = 0.03) and transformation to AML (relative risk 2.63, p = 0.04).
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Myelodysplastic Syndromes / mortality. Tumor Stem Cell Assay
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Risk Factors. Survival Rate


61. Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR: Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant; 2006 Jan;37(1):45-50
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
  • We examined retrospectively 44 patients with refractory acute leukemia (acute myeloid leukemia (AML)/acute lymphoblastic leukemia=25/19) who underwent allogeneic transplantation at our center between 11/1990 and 04/2004.
  • Twenty-one patients had untreated relapse, 13 failed reinduction, eight in partial remission and two aplastic.
  • Severe acute-GVHD and chronic-GVHD appeared in eight and 14 patients, respectively.
  • We conclude that patients with refractory leukemia can benefit from allogeneic BMT, especially with < or =20% marrow blast.
  • [MeSH-major] Blast Crisis / therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Myeloablative Agonists / administration & dosage. Retrospective Studies. Transplantation, Homologous. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258531.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


62. Zhang ZM, Xie ZX, Tan DR, Huang CH: [Detection of glutathione S-transferase and lung resistance-related proteins in acute leukemia and its clinical significance]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Jun;30(3):292-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of glutathione S-transferase and lung resistance-related proteins in acute leukemia and its clinical significance].
  • OBJECTIVE: To explore the relationship among intracellular glutathione S-transferase activity (GST), the expression of lung resistance-related proteins (LRP) in acute leukemia, and its clinical effects.
  • METHODS: The GST activity of bone marrow mononuclear cells and LRP expression in 57 acute leukemia patients were detected by the spectrophotometry assay and immuno-cytochemistry (SABC), respectively.
  • RESULTS: The GST activity of bone marrow mononuclear cells in the acute leukemia group was significantly higher than that of the control group (P < 0.01).
  • The GST activity of mononuclear cells in acute leukemia was positively correlated with the percentage of blast in the bone marrow (r = 0.30, P < 0.05).
  • The GST activity of mononuclear cells in the untreated acute leukemia group was obviously higher than that of the complete remission group (P <0.01).
  • The GST activity in the refractory or relapsed acute leukemia group was significantly higher than that of the complete remission group and untreated leukemia group (P <0.05).
  • CONCLUSION: The increase of GST activity in the bone marrow mononuclear cells is related to the clinical curative effects and the proliferation of blast in acute leukemia.
  • Detection of LRP and GST activities in acute leukemia may have a reference value in judging the leukemia with drug resistance and estimating the prognosis.
  • [MeSH-major] Glutathione Transferase / metabolism. Leukemia, Myeloid, Acute / metabolism. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Cells / metabolism. Child. Female. Humans. Male. Middle Aged. Multidrug Resistance-Associated Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045016.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


63. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP: Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol; 2009 Jan 10;27(2):250-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
  • Sporadic reports on increased incidence of transformation to high-grade non-Hodgkin's lymphoma and development of therapy-related myelodysplasia/acute leukemia (t-MDS/AML) among patients with WM treated with NAs prompted us to examine the incidence of such events in a large population of patients with WM.
  • RESULTS: Overall, 12 patients (6.2%) either developed transformation (n = 9; 4.7%) or developed t-MDS/AML (n = 3; 1.6%) among NA-treated patients, compared with one patient (0.4%) who developed transformation in the non-NA treated group (P < .001); no such events occurred among untreated patients.
  • Transformation and t-MDS/AML occurred at a median of 5 years from onset of NA therapy.
  • However, all NA-treated patients who developed t-MDS/AML died at a median of 5 months.
  • CONCLUSION: These data demonstrate an increased incidence of disease transformation to high-grade NHL and the development of t-MDS/AML among patients with WM treated with NAs.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Leukemia, Myeloid, Acute / pathology. Myelodysplastic Syndromes / pathology. Nucleosides / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy. Waldenstrom Macroglobulinemia / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chlorambucil / therapeutic use. Cladribine / therapeutic use. Female. Follow-Up Studies. Humans. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Retrospective Studies. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use


64. Jenkins C, Hewamana S, Gilkes A, Neelakantan S, Crooks P, Mills K, Pepper C, Burnett A: Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol; 2008 Dec;143(5):661-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
  • This study demonstrated the constitutive activation of NF-kappaB in human myeloid blasts and a clear correlation between NF-kappaB expression and in vitro cytoprotection.
  • High NF-kappaB expression was found in many of the poor prognostic acute myeloid leukaemia (AML) subtypes, such as French-American-British classification M0 and M7, and the poor cytogenetic risk group.
  • The in vitro effects of LC-1, a novel dimethylamino-parthenolide analogue, were assessed in 62 primary untreated AML samples.
  • LC-1 was found to be cytotoxic to AML cells in a dose-dependent manner, mediated through the induction of apoptosis.
  • The median drug concentration necessary to kill 50% of the cells was 4.5 micromol/l for AML cells, compared with 12.8 micromol/l for normal marrow cells.
  • Consequently, LC-1 treatment provides a proof of principle for the use of NF-kappaB inhibitors in the treatment of AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / metabolism. NF-kappa B / antagonists & inhibitors. Sesquiterpenes / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis. Cytotoxicity Tests, Immunologic. Electrophoretic Mobility Shift Assay. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036014.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / LC-1 compound; 0 / NF-kappa B; 0 / Sesquiterpenes
  •  go-up   go-down


65. Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, Gjertsen BT, Bruserud O: Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol; 2007 Sep;79(3):210-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
  • We therefore investigated (i) whether a similar expression pattern could be detected in native human acute myelogenous leukemia (AML) cells and (ii) whether cyclin B1 specific antibodies could be detected in AML.
  • METHODS: AML cell expression of cyclin B1 was analyzed by flow cytometry and confocal microscopy.
  • Humoral immune response in AML patient sera against cyclin B1 was analyzed by ELISA.
  • RESULTS: AML cell expression of cyclin B1 was detected for all 42 patients; but the percentage of cyclin B1 positive cells showed a wide variation between patients.
  • Furthermore, the cytoplasmic expression was maintained after 14 d of in vitro culture and differentiation of the AML cells towards a dendritic cell phenotype.
  • Cyclin B1 specific serum antibodies could be detected for seven of 65 patients with untreated AML.
  • CONCLUSIONS: Our studies demonstrate that primary human AML cells show aberrant cytoplasmic expression of cyclin B1 for a majority of patients and a specific humoral immune response was also detected for a subset of patients with untreated leukemia.
  • [MeSH-major] Antibodies, Neoplasm / blood. Cyclin B / immunology. Cytoplasm / chemistry. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibody Formation. Antigens, Neoplasm. Case-Control Studies. Cell Differentiation. Cell Nucleus / chemistry. Cyclin B1. Dendritic Cells. Enzyme-Linked Immunosorbent Assay. Humans. Mice. Mice, SCID. Middle Aged. Neoplasm Transplantation. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17655707.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 2G12RR008124; United States / NCI NIH HHS / CA / CA56956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / CCNB1 protein, human; 0 / Ccnb1 protein, mouse; 0 / Cyclin B; 0 / Cyclin B1
  •  go-up   go-down


66. Bug G, Atta J, Klein SA, Hertenstein B, Bergmann L, Boehrer S, Mousset S, Hoelzer D, Martin H: High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Ann Hematol; 2005 Oct;84(11):748-54
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
  • In a pilot study high-dose melphalan (HD-Mel, 200 mg/m2) and autologous stem cell transplantation (ASCT) were administered to 14 patients (median age 52, range 29-60 years) with acute myeloid leukaemia (AML) in first relapse after a previous ASCT in first complete remission (n=11) or chemotherapy (n=3).
  • A first cohort of five patients received HD-Mel as salvage therapy after a previous cycle of mitoxantrone, topotecan and cytarabine (MTC) had failed in four out of five patients, while a second cohort of nine patients received HD-Mel in untreated relapse.
  • Our results highly encourage to further investigate HD-Mel and ASCT as a promising salvage regimen for relapsed AML patients for whom autologous peripheral blood stem cells are available.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Melphalan / therapeutic use. Salvage Therapy / methods. Stem Cell Transplantation
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Female. Humans. Karyotyping. Male. Middle Aged. Recurrence. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001243.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


67. Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, Qian J, Jin J, Xu H: Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol; 2009 Nov;158(2):199-204
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia.
  • In this study, we investigated Th17 cell frequency and secretion of related cytokines in patients with acute myeloid leukaemia (AML).
  • First, we found that Th17 cell frequencies were increased significantly in peripheral blood samples from untreated patients with AML, compared with those from healthy volunteers.
  • These results suggest that Th17 cells may play a role in the pathogenesis of AML.
  • In addition, we found that IL-6 and transforming growth factor (TGF)-beta1 concentrations increased in the untreated patients and that IL-6 concentrations showed a positive correlation with the frequencies of Th17 cells, suggesting that IL-6 may play an important role in Th17 cell differentiation in patients with AML.
  • [MeSH-major] Interleukin-17 / blood. Leukemia, Myeloid, Acute / immunology. T-Lymphocyte Subsets / immunology. T-Lymphocytes, Helper-Inducer / immunology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Flow Cytometry / methods. Humans. Interleukin-6 / blood. Male. Middle Aged. Remission Induction. Transforming Growth Factor beta / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2001 Jun;56(6):487-93 [11359967.001]
  • [Cites] Blood. 2001 Feb 1;97(3):624-30 [11157477.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2620-7 [12411307.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):452-5 [14744755.001]
  • [Cites] J Cell Mol Med. 2003 Oct-Dec;7(4):472-4 [14754516.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] AIDS. 1990 Apr;4(4):367-8 [2350458.001]
  • [Cites] Exp Cell Res. 1992 Jul;201(1):160-73 [1612121.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2457-64 [15781662.001]
  • [Cites] Int Arch Allergy Immunol. 2005;137 Suppl 1:51-4 [15947485.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] J Leukoc Biol. 2005 Oct;78(4):946-53 [16033813.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Immunity. 2006 Feb;24(2):179-89 [16473830.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] Nature. 2006 May 11;441(7090):231-4 [16648837.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Cell. 2006 Sep 22;126(6):1121-33 [16990136.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2817-29 [16947782.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):950-7 [17676044.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):2936-46 [17763419.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3804-13 [17693581.001]
  • [Cites] Immunity. 2008 Apr;28(4):445-53 [18400187.001]
  • [Cites] Nat Immunol. 2008 Jun;9(6):650-7 [18454150.001]
  • [Cites] Nat Immunol. 2008 Jun;9(6):641-9 [18454151.001]
  • [Cites] Blood. 2008 Jul 15;112(2):362-73 [18354038.001]
  • [Cites] Nature. 2008 Jul 17;454(7202):350-2 [18469800.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 26;374(3):533-7 [18655770.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):942-9 [17676045.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):933-44 [12461566.001]
  • (PMID = 19737137.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-17; 0 / Interleukin-6; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2768809
  •  go-up   go-down


68. Olsnes AM, Ersvaer E, Ryningen A, Paulsen K, Hampson P, Lord JM, Gjertsen BT, Kristoffersen EK, Bruserud Ø: The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol; 2009 Jun;145(6):761-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.
  • Acute myeloid leukaemia (AML) cells show constitutive release of several chemokines that occurs in three major clusters: (I) chemokine (C-C motif) ligand (CCL)2-4/chemokine (C-X-C motif) ligand (CXCL)1/8, (II) CCL5/CXCL9-11 and (III) CCL13/17/22/24/CXCL5.
  • Ingenol-3-angelate (PEP005) is an activator of protein kinase C and has antileukaemic and immunostimulatory effects in AML.
  • We investigated primary AML cells derived from 35 unselected patients and determined that PEP005 caused a dose-dependent increase in the release of chemokines from clusters I and II, including several T cell chemotactic chemokines.
  • CCL2-4/CXCL1/8 release correlated with nuclear factor (NF)-kappaB expression in untreated AML cells, and PEP005-induced chemokine production was associated with further increases in the expression of the NF-kappaB subunits p50, p52 and p65.
  • To conclude, PEP005 has a unique functional pharmacological profile in human AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diterpenes / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. NF-kappa B / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Chemokines / immunology. Female. Flow Cytometry. Humans. Male. Middle Aged. Protein Kinase C / metabolism. RNA Interference. RNA, Small Interfering / pharmacology. Statistics, Nonparametric. Tumor Cells, Cultured


69. Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP: Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol; 2010 Jun 20;28(18):3035-41
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
  • PURPOSE: The efficacy and safety of cyclophosphamide, vincristine, and prednisone (CVP) followed by tositumomab and iodine-131 ((131)I) -tositumomab therapy were evaluated in a multicenter phase II study in patients with untreated low-grade follicular lymphoma.
  • Two patients developed myelodysplastic syndrome/acute myeloid leukemia.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Feasibility Studies. Follow-Up Studies. Humans. Maximum Tolerated Dose. Middle Aged. Prednisone / administration & dosage. Remission Induction. Survival Rate. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458031.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / iodine-131 anti-B1 antibody; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


70. Martino R, Valcárcel D, Brunet S, Sureda A, Sierra J: Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant; 2008 Jan;41(1):33-8
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.
  • We prospectively compared two strategies of allogeneic PBSCT from HLA-identical siblings in adults with poor-risk AML or myelodysplastic syndrome with >5% marrow blasts in an early disease status (AML or refractory anemia with excess blasts (RAEB type 2) in first remission after chemotherapy or untreated RAEB type 1).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / mortality. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Transplantation Conditioning
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prospective Studies. Transplantation, Homologous


71. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC: Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res; 2008 Mar 1;14(5):1446-54
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
  • PURPOSE: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro.
  • We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML).
  • Nine patients had relapsed AML (ages, 18-59 years, n = 4 and > or = 60 years, n = 5).
  • There were 22 patients of > or = 60 years with previously untreated AML (eight with prior myelodysplasia/myeloproliferative disorder or cytotoxic therapy).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Boronic Acids / administration & dosage. Bortezomib. Cohort Studies. Cytarabine / administration & dosage. Female. Gene Expression Profiling. Humans. Idarubicin / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Oligonucleotide Array Sequence Analysis. Pyrazines / administration & dosage. Tissue Distribution. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316568.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA066996
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Boronic Acids; 0 / Pyrazines; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib; ZRP63D75JW / Idarubicin
  •  go-up   go-down


72. Wu YJ, Li JY, Zhu MQ, Song JH, Zheng WJ: [Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jul;27(7):449-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens].
  • OBJECTIVE: To explore the diagnostic value of intracellular antibody combination in acute leukemia (AL) expressing cross-lineage cell-surface antigens.
  • METHODS: Flow cytometric immunophenotyping using intracellular antibody combination (cMPO/cCD79alpha/cCD3/CD45) was performed additionally in 60 patients who expressed cross-lineage antigens from 269 previously untreated adult AL.
  • RESULTS: Fifty-four of 269 previously untreated adult AL patients who expressed only one kind of intracellular antigen were diagnosed as cross-lineage AL, the percentage of cross-lineage AL in T cell acute lymphoblastic leukemia (T-ALL), B-ALL and acute myeloid leukemia (AML) was 28.6%, 43.6% and 13.4%, respectively.
  • The positive rate of CD7, CD19, CD5 and CD20 in cross-lineage AML was 65.4%, 15.4%, 11.5%, and 7.7%, respectively.
  • Six (2.3%) patients expressed two-lineage intracellular antigens were diagnosed as biphenotypic AL: 2 of T/B type and 4 B/M (B/myeloid) type.
  • [MeSH-major] Antibodies, Monoclonal. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD3 / immunology. Antigens, CD45 / immunology. Antigens, CD79 / immunology. Antigens, Surface / immunology. Cross Reactions. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147246.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD3; 0 / Antigens, CD79; 0 / Antigens, Surface; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


73. Xu J, Xu CG, Liu T, Xiang B, Chang H, He C: [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan;40(1):129-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
  • OBJECTIVE: To evaluate the effectiveness and toxicity of the regimen combined homoharringtonine, low-dose cytarabine with G-CSF or GM-CSF (HAG regimen) in treating patients with relapsed or refractory AML, geriatric AML and advanced myelodysplastic syndromes (MDS).
  • METHODS: Forty patients with AML or advanced MDS were treated with HAG regimen for remission induction and consolidation therapy.
  • Results 20 of them (50%) achieved complete remission (CR), including 46.2% patients with relapsed or refractory AML, 60% elderly patients with primary AML who were either untreated or treated with only one course of induction therapy previously, and 66.7% patients with MDS-RAEB.
  • It seems promising for the treatment of relapsed or refractory AML, geriatric AML and advanced MDS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytarabine / administration & dosage. Female. Follow-Up Studies. Harringtonines / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Young Adult


74. Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K, Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R: Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. Int J Hematol; 2010 Jan;91(1):97-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
  • A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG).
  • Untreated adult patients with high-risk MDS and MDS-AML were randomly assigned to receive either idarubicin and cytosine arabinoside (IDR/Ara-C) (Group A) or low-dose cytosine arabinoside and aclarubicin (CA) (Group B).
  • In conclusion, it is necessary to introduce the first line therapy excluding the chemotherapy that can prolong survival in patients with high-risk MDS and MDS-AML.
  • [MeSH-major] Aclarubicin / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Female. Humans. Japan. Male. Middle Aged. Remission Induction. Risk Factors. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20047095.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 74KXF8I502 / Aclarubicin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


75. Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR: Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant; 2006 Jul;12(7):749-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
  • We analyzed outcomes of patients with myelodysplastic syndrome (MDS) or secondary acute myelogenous leukemia (sAML) that were treated at our institution with a reduced intensity conditioning (RIC) regimen of 550-cGy total body irradiation and cyclophosphamide followed by related donor (RD) or unrelated donor (URD) transplantation.
  • With a median follow-up of 3.7 years after transplantation in the 19 surviving patients (37%), Kaplan-Meier estimates of overall survival were 88%, 46%, 33%, and 11% for patients transplanted with sAML in remission, refractory anemia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or sAML refractory/untreated, respectively.
  • [MeSH-major] Bone Marrow Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Cyclophosphamide / therapeutic use. Female. Graft Survival. Graft vs Host Disease / etiology. Humans. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Radiotherapy Dosage. Recurrence. Retrospective Studies. Survival Analysis. Whole-Body Irradiation / methods


76. Wu YH, Zou P, Liu F, Shen HB: [Expression of survivin in leukemia cells and influence on it by GM-CSF]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb;15(1):6-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of survivin in leukemia cells and influence on it by GM-CSF].
  • This study was aimed to explore the expression of survivin in leukemia cells and to investigate the effect of GM-CSF on survivin expression.
  • The survivin expressions in 37 previously untreated leukemia patients and 10 normal persons as well as in three kinds of leukemia cell lines (K562, HL-60, U937) were analyzed by RT-PCR.
  • The results indicated that the positive rate of survivin gene in 37 leukemia patients was 67.6% (25/37) and significantly higher than that in normal control (20.0%).
  • The expression level was higher in ALL cells than that in AML cells (73.3% vs 63.6%).
  • Moreover, three kinds of leukemia cell lines all expressed survivin.
  • It is concluded that the survivin gene extensively express in leukemia and its cell lines, and its expression can be obviously increased by GM-CSF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490510.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


77. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM: A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res; 2009 Nov 1;15(21):6732-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
  • PURPOSE: Inhibiting mammalian target of rapamycin (mTOR) signaling in acute myelogenous leukemia (AML) blasts and leukemic stem cells may enhance their sensitivity to cytotoxic agents.
  • We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy.
  • EXPERIMENTAL DESIGN: We performed a phase I dose escalation study of sirolimus with the chemotherapy regimen MEC (mitoxantrone, etoposide, and cytarabine) in patients with relapsed, refractory, or untreated secondary AML.
  • Future studies are planned with different schedules to clarify the clinical and biochemical effects of sirolimus in AML and to determine whether target inhibition predicts chemotherapy response.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Sirolimus / administration & dosage
  • [MeSH-minor] Adult. Aged. Carboplatin / therapeutic use. Drug Administration Schedule. Drug Resistance, Neoplasm. Etoposide / therapeutic use. Female. Humans. Male. Maximum Tolerated Dose. Melphalan / therapeutic use. Middle Aged. Protein Kinases / metabolism. Recurrence. Signal Transduction. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843663.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; Q41OR9510P / Melphalan; W36ZG6FT64 / Sirolimus; MEC regimen
  •  go-up   go-down


78. Huang HH, Zhu JY, Zhong JH, Wang HR, Zhong H, Han JY, Chen FY: [Correlation between expression of apoptosis-related gene pnas-2 and leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):738-42
Hazardous Substances Data Bank. ARSENIC TRISULFIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between expression of apoptosis-related gene pnas-2 and leukemia].
  • The study was purposed to explore the correlation between apoptosis-related gene pnas-2 and leukemia.
  • The RT-PCR was performed to detect the expression levels of pnas-2 gene in NB4, K562, U937 cells before and after treatment with AS(4)S(4), and to analysis the expression change of pnas-2 gene in bone marrow cells from patients with acute leukemia before and after chemotherapy.
  • The positive expression rate of pnas-2 in cells from untreated patients with acute leukemia was 100%, and was significantly higher than that in normal control group.
  • It is concluded that the pnas-2 gene may be closely related with apotosis of arsenic sulfide treated APL cells, and may consider as a molecular biological remission marker in acute leukemia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708794.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Arsenicals; 0 / PNAS-2 protein, human; 0 / Sulfides; 44SIJ800OX / arsenic trisulfide
  •  go-up   go-down


79. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP: Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood; 2006 Nov 15;108(10):3271-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
  • We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients.
  • Among 10 elderly patients with acute myelogenous leukemia or myelodysplastic syndrome, 5 (50%) had a response (4CRs, 1CRp's).
  • In summary, this combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks.
  • [MeSH-major] Azacitidine / analogs & derivatives. Leukemia / drug therapy. Valproic Acid / administration & dosage
  • [MeSH-minor] Acetylation / drug effects. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. DNA Methylation / drug effects. Epigenesis, Genetic / drug effects. Histone Deacetylase Inhibitors. Histones / metabolism. Humans. Leukemia, Myeloid, Acute / drug therapy. Middle Aged. Myelodysplastic Syndromes / drug therapy. Remission Induction / methods. Survival Analysis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Nov 1;100(9):3432-3; author reply 3433-4 [12412576.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2957-64 [12351408.001]
  • [Cites] Blood. 2003 May 15;101(10):4131-6 [12586619.001]
  • [Cites] CNS Drug Rev. 2003 Summer;9(2):199-216 [12847559.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):344-51 [12901942.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1266-9 [15155466.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):151-8 [15324698.001]
  • [Cites] Neurology. 1987 Mar;37(3):379-85 [3102998.001]
  • [Cites] Drugs. 1994 Feb;47(2):332-72 [7512905.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):323-8 [10472571.001]
  • [Cites] Leuk Res. 2005 Jul;29(7):739-48 [15927669.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3948-56 [15883410.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):101-9 [15895376.001]
  • [Cites] Cancer Invest. 2005;23(7):635-42 [16305991.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S30-5 [16341238.001]
  • [Cites] Leukemia. 2006 Feb;20(2):212-7 [16357841.001]
  • [Cites] Semin Cancer Biol. 1999 Oct;9(5):339-47 [10547342.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):956-62 [10694544.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 [10954755.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Blood. 2001 May 1;97(9):2823-9 [11313277.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36734-41 [11473107.001]
  • [Cites] Nature. 2001 Nov 15;414(6861):258-61 [11713509.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):6969-78 [11742974.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):662-4 [11895892.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2217-24 [12114423.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):206-15 [12482974.001]
  • (PMID = 16882711.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00075010
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 0 / Histones; 614OI1Z5WI / Valproic Acid; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC1895437
  •  go-up   go-down


80. Denz U, Bertz H, Ihorst G, Wäsch R, Finke J: Improved outcome in relapsed and refractory myeloid malignancies for unrelated vs related donor allogeneic peripheral blood-derived hematopoietic cell transplantation. Bone Marrow Transplant; 2010 Aug;45(8):1309-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in relapsed and refractory myeloid malignancies for unrelated vs related donor allogeneic peripheral blood-derived hematopoietic cell transplantation.
  • There are limited data on the comparison of unrelated vs related peripheral blood-derived hematopoietic cell transplantation (HCT) in patients with AML and its implications in high-risk patients.
  • In this single-center retrospective study, we report on a total of 92 consecutive patients with AML (n=87) or myelodysplastic syndrome (MDS; n=5), who were treated between 1996 and 2006 with a uniform preparative regimen of BU and CY and peripheral blood-derived HCT from related (n=46) or unrelated donors (n=46).
  • At transplantation, 45 patients were in CR, 11 were untreated and 36 had relapsed or refractory disease.
  • Unrelated HCT benefited high-risk AML patients with an unfavorable remission status better than related HCT.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods. Tissue Donors
  • [MeSH-minor] Adolescent. Adult. Cyclophosphamide / therapeutic use. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Transplantation, Homologous. Treatment Outcome. Young Adult


81. Auberger J, Clausen J, Willenbacher W, Erdel M, Gunsilius E, Petzer A, Gastl G, Nachbaur D: Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience. Int J Hematol; 2008 May;87(4):382-6
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.
  • Disease recurrence has been and remains the leading cause of treatment failure in patients with high-risk leukemia.
  • We retrospectively analyzed outcome in 61 patients with high-risk leukemia receiving a combination of fludarabine and intermediate-dose cytarabine as induction (n = 11) or salvage therapy (n = 35).
  • In patients without prior allogeneic HSCT (n = 46) the complete remission rate (CR) was 41% with a CR rate of 46 and 14% in patients with acute myeloid leukemia (AML) and with acute lymphoblastic leukemia (ALL), respectively.
  • By multivariate analysis achieving CR, receiving an allogeneic HSCT, and being in first relapse or untreated were the only parameters that significantly determine the outcome.
  • Although preliminary only high-risk AML patients having a stem cell donor are candidates for fludarabine/intermediate-dose cytarabine and only those achieving a CR should be referred to subsequent allogeneic HSCT.
  • All other patients with high-risk leukemia are candidates for experimental therapies within controlled trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Recurrence. Risk Factors. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418698.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


82. Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD, McConkey C, Child JA, Cunningham D, Morgan GJ, Catovsky D, National Cancer Research Institute Haematological Studies Group: Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood; 2005 Jan 01;105(1):397-404
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses.
  • We have assessed autologous stem cell transplantation after treatment with fludarabine in previously untreated patients with chronic lymphocytic leukemia (CLL).
  • This study is the first to enroll previously untreated patients and follow them prospectively.
  • It is of concern that 5 of 65 (8%) patients developed posttransplant acute myeloid leukemia/myelodysplastic syndrome.
  • [MeSH-major] Aging / physiology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Transplantation, Autologous / immunology
  • [MeSH-minor] Adult. Disease Progression. Female. Follow-Up Studies. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged. Myelodysplastic Syndromes / complications. Neoplasm, Residual / pathology. Pilot Projects. Survival Rate

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15117764.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0001160
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


83. Gupta SK, Sazawal S, Mahapatra M, Saxena R: Evaluation of PG-M3 antibody in the diagnosis of acute promyelocytic leukaemia. Eur J Clin Invest; 2010 Oct;40(10):960-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of PG-M3 antibody in the diagnosis of acute promyelocytic leukaemia.
  • BACKGROUND & OBJECTIVES: Acute promyelocytic leukaemia (APL) is a distinct subtype of acute myeloid leukaemia (AML) characterized by a reciprocal translocation, t(15;17) and a high incidence of life-threatening coagulopathy.
  • MATERIALS AND METHODS: Thirty-six new untreated APL cases diagnosed with RT-PCR for PML-RAR as the gold standard and 38 non-APL controls (28 non-APL AMLs and 10 non-leukaemic samples) were evaluated by routine morphology and cytochemistry, RT-PCR and IF using PG-M3 monoclonal antibody.
  • [MeSH-major] Antibodies, Monoclonal. Leukemia, Promyelocytic, Acute / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Child. Female. Fluorescent Antibody Technique / economics. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.
  • (PMID = 20701624.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


84. Lindhagen E, Eriksson A, Wickström M, Danielsson K, Grundmark B, Henriksson R, Nygren P, Aleskog A, Larsson R, Höglund M: Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol; 2008 Nov;81(5):344-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
  • We have investigated the activity of gefitinib in haematological tumour cells, in particular acute myeloblastic leukaemia (AML).
  • In AML, the EGFR status was analysed by immunochemistry.
  • Gefitinib-induced apoptosis was investigated in a subset of AML samples, as well as in the leukaemia cell line MV-4-11, using a multiparametric high content screening assay.
  • RESULTS: Gefitinib showed highest cytotoxic activity in AML (n = 19) with many samples being sensitive at concentrations achievable in clinical practice (<10 microM), and no difference between previously untreated and relapsed patients.
  • The AML cells did not express the EGFR.
  • CONCLUSION: In vitro, gefitinib has significant cytotoxic activity in AML by inducing apoptosis through non-EGFR dependent pathways.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Leukemia, Myeloid, Acute / drug therapy. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Caspase 3 / metabolism. Drug Screening Assays, Antitumor / methods. Female. Humans. Immunochemistry. Male. Middle Aged. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637032.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; S65743JHBS / gefitinib
  •  go-up   go-down


85. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H: Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol; 2005 Apr 20;23(12):2805-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
  • PURPOSE: To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS).
  • PATIENTS AND METHODS: Patients with relapsed or refractory acute leukemias or MDS, or previously untreated but poor candidates for chemotherapy, were included in this phase I study with a 3 + 3 dose escalation design.
  • Five patients had evidence of antileukemia activity, including two with complete remission with incomplete platelet recovery, one with hematologic improvement, and two with morphologic leukemia-free state.
  • Further investigation of this agent in leukemia is warranted.
  • [MeSH-major] Benzodiazepines / adverse effects. Benzodiazepines / therapeutic use. Imidazoles / adverse effects. Imidazoles / therapeutic use. Leukemia, Myeloid / drug therapy. Myelodysplastic Syndromes / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15728224.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine; 0 / Imidazoles; 12794-10-4 / Benzodiazepines
  •  go-up   go-down


86. Sultana TA, Abdul Mottalib M, Islam S, Khan MA, Choudhury S: Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh. Bangladesh Med Res Counc Bull; 2008 Apr;34(1):1-11
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nested reverse-transcriptase polymerase chain reaction (rt-PCR) was performed on 58 leukemia patients at BIRDEM Laboratory, as a pioneering work in Bangladesh.
  • Thirty of themwere examined for the presence of BCR-ABL being clinically and morphologically diagnosed as chronic myeloid leukemia (CML) and 28 for PML-RARalpha fusion transcripts being clinically and morphologically diagnosed as acute promyelocytic leukemia (APL/ AML M3).
  • In case of BCR-ABL, positive results were found for five out of six (83.33%) untreated cases and 11 out of 24 (45.83%) treated cases.
  • Positive results for PML-RARalpha were found for 12 out of 14 (85.70%) untreated cases and 11 out of 16 (68.75%) treated cases.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Promyelocytic, Acute / diagnosis. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Bangladesh. Benzamides. Child. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / therapeutic use. Prospective Studies. Pyrimidines / therapeutic use. Treatment Outcome. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783070.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5688UTC01R / Tretinoin; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


87. Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E: Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood; 2005 Aug 1;106(3):803-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The time until 25% developed acute myeloid leukemia (AML) was longer in the good and intermediate predictive groups for erythroid response compared with the poor predictive group (52 versus 13 months, P = .008).
  • Only 1 of 20 long-term responders developed AML.
  • We assessed the effect on long-term outcome by comparing treated patients with untreated patients selected from the IPSS database using multivariate Cox regression, adjusting for major prognostic variables.
  • There was no difference in survival (odds ratio [OR], 0.9; 95% confidence interval [CI], 0.7-1.2; P = .55) or risk of AML evolution (OR, 1.3; 95% CI, 0.7-2.2; P = .40) between treated and untreated patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Cell Transformation, Neoplastic. Female. Humans. Leukemia, Myeloid / etiology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Survival Analysis. Treatment Outcome


88. Aschoff P, Häntschel M, Oksüz M, Werner MK, Lichy M, Vogel W, Pfannenberg C: Integrated FDG-PET/CT for detection, therapy monitoring and follow-up of granulocytic sarcoma. Initial results. Nuklearmedizin; 2009;48(5):185-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Granulocytic sarcomas (GS) are rare extramedullary manifestations of myeloid or lymphoblastic leukaemia.
  • RESULTS: 52 untreated or recurrent GS lesions were detected by FDG-PET/CT and all showed an increased FDG uptake with a mean SUVmax and SUVavg of 5.1 and 3.4, respectively.
  • [MeSH-major] Sarcoma, Myeloid / radionuclide imaging
  • [MeSH-minor] Adult. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / radiography. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / radionuclide imaging. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / radiography. Leukemia, Myeloid, Acute / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19710955.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


89. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM: The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer; 2005 May 15;103(10):1985-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since then, clofarabine has demonstrated single-agent antitumor activity in pediatric and adult acute leukemias.
  • Combinations of clofarabine with cytarabine have been studied in acute leukemia and currently are being evaluated in untreated elderly patients with acute myeloid leukemia.
  • Clofarabine is a new nucleoside analog with considerable activity and an acceptable safety profile in acute leukemias.
  • [MeSH-minor] Adenine Nucleotides. Adult. Aged. Child. Humans. Leukemia / drug therapy. Lymphoproliferative Disorders / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803490.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101354; United States / NCI NIH HHS / CA / CA55164; United States / NCI NIH HHS / CA / CA57629; United States / NCI NIH HHS / CA / CA81534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  • [Number-of-references] 48
  •  go-up   go-down


90. Aljurf M, Al Qurashi F, Al Mohareb F, Sahovic E, Al Sharif F, Al Zahrani H, Al Shanqeeti A, Owaidah T, Iqbal A, Zaidi SZ, Nurgat ZA, Sanz M, Chaudhri N: High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA. Med Oncol; 2010 Sep;27(3):702-7
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute promyelocytic leukemia (APL) is one of the most curable myeloid malignancies because of its great sensitivity to all-trans retinoic acid (ATRA) and response to anthracycline therapy.
  • In an attempt to simplify post-remission therapy, deliver adequate dose of anthracycline and reduce treatment related toxicity, we entered 26 consecutively newly diagnosed, previously untreated APL patients in a pilot treatment program consisting of concurrent induction using idarubicin/ATRA followed by an exclusive outpatient post-remission therapy using single dose of idarubicin and intermittent ATRA, every 4 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Ambulatory Care. Clinical Trials as Topic / statistics & numerical data. Dexamethasone / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Factor VIII / therapeutic use. Female. Fibrinogen / analysis. Fibrinogen / therapeutic use. Hemorrhage / chemically induced. Hemorrhage / drug therapy. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Kaplan-Meier Estimate. Male. Middle Aged. Pilot Projects. Remission Induction. Tretinoin / administration & dosage. Tretinoin / adverse effects. Young Adult

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19669610.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / cryoprecipitate coagulum; 5688UTC01R / Tretinoin; 7S5I7G3JQL / Dexamethasone; 9001-27-8 / Factor VIII; 9001-32-5 / Fibrinogen; ZRP63D75JW / Idarubicin
  •  go-up   go-down


91. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood; 2008 Feb 1;111(3):1060-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia.
  • Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible.
  • Of 41 patients, 31 had acute myeloid leukemia (AML), 4 chronic lymphocytic leukemia, 3 MDS, 2 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia.
  • There were no drug-related deaths; 7 patients had hematologic improvement response, including 2 complete responses and 2 complete responses with incomplete blood count recovery (all with AML treated at/below MTD).
  • Further evaluation of vorinostat in AML/MDS is warranted.
  • [MeSH-major] Enzyme Inhibitors / therapeutic use. Histone Deacetylase Inhibitors. Hydroxamic Acids / therapeutic use. Leukemia / drug therapy. Leukemia / pathology. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Acetylation. Adolescent. Adult. Aged. Aged, 80 and over. Clinical Trials, Phase I as Topic. Dose-Response Relationship, Drug. Drug Tolerance. Drug-Related Side Effects and Adverse Reactions. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Histone Deacetylases / metabolism. Histones / metabolism. Humans. Male. Middle Aged. Neoplasm Staging


92. Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C: Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia; 2006 Oct;20(10):1840-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-two untreated FL patients aged <or=60 were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis.
  • (4) actuarial 5-years risk of developing secondary myelodysplasia and acute myeloid leukemia of 3.7%, with most of these events occurring in patients re-treated for recurrent lymphoma.
  • [MeSH-minor] Adolescent. Adult. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Follow-Up Studies. Humans. Incidence. Middle Aged. Neoplasm Recurrence, Local / mortality. Prednisone / administration & dosage. Prednisone / adverse effects. Risk Factors. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932351.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; DHAP protocol; VPD protocol
  •  go-up   go-down


93. Keros V, Hultenby K, Borgström B, Fridström M, Jahnukainen K, Hovatta O: Methods of cryopreservation of testicular tissue with viable spermatogonia in pre-pubertal boys undergoing gonadotoxic cancer treatment. Hum Reprod; 2007 May;22(5):1384-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We wanted to find optimal methods for cryopreservation of testicular tissue from pre-pubertal boys, modifying techniques developed for fetal and adult human testicular tissue cryopreservation.
  • Two freezing protocols, originally developed for fetal and adult human testicular tissue, were applied for pre-pubertal testicular tissue cryopreservation.
  • We also analysed frozen-thawed samples cultured for 24 h in comparison with untreated fresh fixed control tissue.
  • RESULTS: No clear structural changes were observed in the fresh, fresh cultured and cryopreserved testicular tissue after using the protocol developed for adult testicular tissue.
  • [MeSH-minor] Adolescent. Cells, Cultured. Child. Child, Preschool. Cryoprotective Agents. Dimethyl Sulfoxide. Humans. Immunohistochemistry. Leukemia, Myeloid, Acute / radiotherapy. Leukemia, Myelomonocytic, Acute / radiotherapy. Male. Microscopy. Microscopy, Electron, Transmission. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Puberty. Rhabdomyosarcoma / radiotherapy. Sertoli Cells / physiology. beta-Thalassemia / radiotherapy

  • Genetic Alliance. consumer health - Testicular cancer.
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259225.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cryoprotective Agents; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


94. Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Westerman D: Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica; 2006 Nov;91(11):1546-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophosphamide or mitoxantrone due to synergistic effects on the inhibition of DNA repair.
  • The crude rate of MDS/sAML was 2.5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Drug Therapy, Combination. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082012.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


95. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ: Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant; 2008 Apr;14(4):458-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1985 to 2004, 49 patients with advanced myelodysplastic syndromes (MDS) (> or =5% blasts) or acute myeloid leukemia (AML) transformed from MDS underwent T cell depleted bone marrow or peripheral blood hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings following conditioning with a myeloablative regimen that included total body irradiation (44 patients) or busulfan (5 patients).
  • Only 3 patients developed acute GVHD (aGVHD) (grades I and III) and 1 chronic GVHD (cGVHD).
  • At 3 yrs post-transplantation, the overall survival (OS) was 54% in the responders; 31% in the untreated group; and 0% in the failure group (P=.0004).
  • The cumulative incidence (CI) of relapse at 2-yrs post-transplantation for the responders was 23%; for the untreated group was 38%; and for the failures was 50%.
  • The CI of non-relapse mortality at 2-yrs post-transplantation, for the responders was 23%; for the untreated group was 38%; and for the failures was 40%.
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Graft vs Host Disease / prevention & control. Humans. Middle Aged. Remission Induction. Retrospective Studies. Siblings. Transplantation Conditioning / methods. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342789.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / NCI NIH HHS / CA / P30 CA008748; United States / NHLBI NIH HHS / HL / R01 HL088134
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Other-IDs] NLM/ NIHMS43830; NLM/ PMC4498391
  •  go-up   go-down


96. Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, Maisonneuve H, Delwail V, Gressin R, Quittet P, Vilque JP, Desablens B, Jaubert J, Ramée JF, Arakelyan N, Thyss A, Moluçon-Chabrot C, Delépine R, Milpied N, Colombat P, Deconinck E, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS): High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood; 2009 Jan 29;113(5):995-1001
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The multicenter study randomized 172 patients with untreated FL for either immunochemotherapy or high-dose therapy (HDT) followed by purged ASCT.
  • Secondary malignancies were more frequent in the HDT than in the chemotherapy group (6 secondary myelodysplastic syndrome/acute myeloid leukemia and 6 second solid tumor cancers vs 1 acute myeloid leukemia, P = .01).
  • [MeSH-minor] Adolescent. Adult. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunotherapy / methods. Male. Middle Aged. Myeloablative Agonists / administration & dosage. Survival Rate. Transplantation, Autologous. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955565.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00696735
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


97. Negaard HF, Iversen PO, Ostenstad B, Mowinckel MC, Sandset PM: Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost; 2008 Sep;6(9):1482-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS/METHODS: Blood samples from 93 patients with acute myeloid leukemia (AML), chronic lymphatic leukemia, multiple myeloma, or non-Hodgkin's lymphoma, were analyzed before start and after completion of cancer therapy.
  • RESULTS: Untreated patients were found to have higher APC-SR than healthy controls, and patients with AML had higher APC-SR as compared to the other diagnoses, both findings being consistent with acquired APC resistance.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573186.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down






Advertisement